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The first experimental attempts of liver transplantation on dogs were in 1955 by 
Welch1. In 1963 Thomas E. Starzl and colleagues started human liver transplantation2. 
Like the first two of these operations in the Netherlands in Leiden and Arnhem in 1966 
and 1968 respectively, these were unsuccesfull auxiliary liver transplantations. 
Operation technique and medication apparently were not yet ready. After a self-
imposed moratorium and more animal experiments Thomas E. Starzl in Denver and 
also Sir Roy Calne in Cambridge started human orthotopic liver transplantation (OLT) in 
1978, and in the Netherlands the fifth center worldwide started in Groningen in 1979 
(Gips, Kootstra and Krom). In 1983 at a National Institutes of Health Consensus 
Development Conference it was decided that liver transplantation was no longer 
experimental and deserved broader application in clinical practice3. Nowadays 
thousands of OLTs have been performed successfully. The one-year survival is 90% and 
the 5-year survival over 80% in many centers. This is due to many factors like 
improved operative technique, better prevention, recognition and treatment of 
complications, and improved immunosuppression. 
The first use of immunosuppressive agents in OLT was in 1966 with a prednisolone and 
azathioprine schedule derived from the successful kidney transplantations4. The 
breakthrough of the use of immunosuppressive agents in OLT was in 1980, the 
development of cyclosporine, a calcineurin-inhibitor. Cyclosporine was effective in the 
prevention of rejection and there was an increase in the survival rate after OLT5-9.  
Later on, other immunosuppressants like tacrolimus (FK-506, another calcineurin 
inhibitor) and mycophenolate mofetil (MMF) were introduced for prevention of graft-loss 
due to rejection. With the success of these agents the focus is now shifting towards 
reduction of side-effects from these drugs, including renal insufficiency from calcineurin 
inhibitors. Therapeutic drug monitoring (TDM) is an important tool for achieving these 
goals. This thesis focuses on TDM of cyclosporine, tacrolimus and mycophenolate 
mofetil after OLT. 
 
Cyclosporine 
The drug cyclosporine (Neoral®) is a cyclic polypeptide immunosuppressant agent 
consisting of 11 amino acids. It is produced as a metabolite by the fungus species 
Beauveria nivea. The effectiveness of cyclosporine results from specific and reversible 
inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. 
T-lymphocytes are preferentially inhibited. The T-helper cell is the main target, 
although the T-suppressor cell may also be suppressed. Cyclosporine also inhibits 




Tacrolimus (Prograf®), previously known as FK506, is a macrolide immunosuppressant 
produced by Streptomyces tsukubaensis. Tacrolimus inhibits T-lymphocyte activation, 
although the exact mechanism of action is not known. Experimental evidence suggests 
that tacrolimus binds to an intracellular protein, FKBP-12. A complex of  
tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the 
phosphatase activity of calcineurin inhibited. This effect may prevent the 
dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a 
nuclear component thought to initiate gene transcription for the formation of 
lymphokines (such as interleukin-2, gamma interferon). The net result is the inhibition 

























Figure 1: Mechanism of action of cyclosporine and tacrolimus  
Mycophenolate mofetil 
Mycopheonale mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an 
immunosuppressive agent, which is an inosine monophosphate dehydrogenase (IMPDH) 
inhibitor. Mycophenolate mofetil is rapidly absorbed following oral administration and 
hydrolyzed to form MPA, which is the active metabolite. MPA is a potent, selective, 
uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase 
(IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis 
without incorporation into DNA. Because T- and B-lymphocytes are critically dependent 
for their proliferation on de novo synthesis of purines, whereas other cell types can 
utilize salvage pathways, MPA has potent cytostatic effects on lymphocytes. MPA 
inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and 
allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the 
cytostatic effects of MPA on lymphocytes. MPA also suppresses antibody formation by 
B-lymphocytes. MPA prevents the glycosylation of lymphocyte and monocyte 
glycoproteins that are involved in intercellular adhesion to endothelial cells and may 
inhibit recruitment of leukocytes into sites of inflammation and graft rejection. 
Mycophenolate mofetil did not inhibit early events in the activation of human peripheral 
blood mononuclear cells, such as the production of interleukin-1 (IL-1) and interleukin-
2 (IL-2), but did block the coupling of these events to DNA synthesis and proliferation12 
(Figure 2). 


















Figure 2: Mechanism of action of mycophenolate mofetil  
Therapeutic drug monitoring 
Calcineurin inhibitors (cyclosporine and tacrolimus) are characterized by a narrow 
therapeutic window. Underdosing may lead to acute or chronic rejection of the graft, 
while overdosing may lead to adverse effects, like elevated blood pressure and 
nephrotoxicity. Therefore accurate dosing of these drugs is warranted. 
When using therapeutic drug monitoring (TDM) dosing is based on measured drug-
concentrations in blood. Dependent on these concentrations the dose is adjusted. 
Especially for medication with a narrow therapeutic range the use of TDM is very useful. 
This is exactly the reason why in the past decades many studies have been performed 
to develop different strategies for TDM in organ transplantation. 
 
Trough concentration (C0) monitoring 
For many years trough concentration or C0 monitoring was generally accepted as the 
best way of monitoring cyclosporine and tacrolimus. This means that dose and possible 
dose adjustments were based on the blood concentration sample just before taking the 
medication. Both cyclosporine and tacrolimus are mostly dosed twice daily, which 
means that a predose-level (C0) is taken approximately 12 hours after the last dose. 
C0-monitoring was proven to be effective in reducing rejections and adverse events. 
Later, the question arised whether C0-monitoring was the optimal way of therapeutic 
drug monitoring, particularly for cyclosporine. Studies showed that the correlation of C0 
with the area under the concentration time curve for 12 hours (AUC0-12) was poor and 
that other time sampling points may better reflect systemic exposure of cyclosporine 
for a dosing interval. Subsequently, a new widely introduced strategy for cyclosporine 
was C2-monitoring. 
For tacrolimus nowadays C0-monitoring is still the common strategy in most clinics. 
 
Fixed dose regimens 
In contrast to the calcineurin inhibitors cyclosporine and tacrolimus, there is no 
consensus on the need for therapeutic drug monitoring of mycophenolate mofetil 
(MMF). Most centers adhere to fixed dose regimens, which means that dosing is not 
based on blood concentrations or other clinical properties like weight, co-medication or 
liver and kidney function. Recently, different strategies were studied including  
C0-monitoring, but there seemed to be a weak correlation between C0 and AUC. 
 
Limited sampling strategies 
The exposition to a drug is determined by the „gold standard AUC‟. Which is 
approximated by taking blood samples every hour and integrating these data with the 
„trapezoidal rule‟. Next to (fixed) single time points as a basis for therapeutic drug 
monitoring of immunosuppressive drugs also limited sampling strategies have been 
developed in the past decade. This means that multiple blood sampling time points are 
used in a formula or model as a surrogates for the „gold standard‟ AUC0-12h. Most of 
these strategies are using limited sampling formulas (LSF algorithms). These have the 
disadvantage that the blood sampling needs to be performed exactly on time, which is 
difficult in an outpatient clinic. 
 
Modeling based on Bayesian estimation 
Few studies have been performed on the development of limited sampling models 
(LSM) based on Bayesian estimation, a statistical method successfully used in 
pharmacy but also other fields of medicine. The advantage of these models is that they 
are flexible, accurate and easy to apply in practice without the need to take blood 
samples exactly on time. As long as the sampling time is noted, these limited sampling 
models (LSMs) are accurate, in contrast to the rigid limited sampling formulas (LSFs), if 
blood is not drawn exactly on time. 
 
Aim of the thesis 
In this thesis we try to optimize the therapeutic drug monitoring of cyclosporine, 
tacrolimus and mycophenolate mofetil in liver transplant patients with limited sampling 
strategies and modelling, using Bayesian estimation. 
Recent literature from studies -more performed in kidney than liver transplantation- 
suggested that a new way of monitoring cyclosporine in organ transplantation patients 
(C2-monitoring) better predicted the systemic exposure to the drug over the first 12 
hours after dosing than C0-monitoring did, which may lead to improved clinical  
outcome13-26. C2 was then recommended for monitoring cyclosporine. Due to this 
recommendation in chapter 2 we switched our stable patients more than 6 months 
after OLT from C0-monitoring towards C2-monitoring and investigated the influence of 
this switch on factors as dose, creatinine clearance (CRCL), blood pressure and freedom 
from rejection and the relationships of C0 and C2 with the gold standard AUC0-12h.  
In chapter 3 we were looking for even better methods for monitoring cyclosporine27. 
We developed and validated an easy to use, accurate and flexible individualized 
Bayesian population-pharmacokinetic (POP-PK) limited sampling model (LSM) 
integrating all available information, without the need for fixed blood sampling time 
points. Different limited sampling models were tested and the correlation of these 
models with the „gold standard‟ AUC0-12h was calculated, in order to predict the 
systemic exposure of cyclosporine very precisely with a limited number of blood 
samples.  
The limited sampling model with time points 0 + 1 + 2 + 3h was then introduced into 
our clinic28. In chapter 4 we evaluated the patients who were previously switched from 
C0 to C2 and now switched to LSM 0,1,2,3h after using this model in our clinic for over 
18 months. This allowed us to investigate the feasibility of implementation of LSM in 
practice, and the potential effects on factors as dose, renal function and rejection rate 
of the three monitoring strategies, and also inter- and intrapatient variability in 
pharmacokinetics of cyclosporine using LSM. We determined the required precision of 
the method used and a new target range for cyclosporine AUC was calculated.  
 
Another frequently used calcineurin inhibitor, tacrolimus, is just as cyclosporine 
characterized by a narrow therapeutic range. This underlines the need of accurate 
monitoring to prevent rejection and adverse events for this drug as well. The 
monitoring of tacrolimus is still based on C0-monitoring in most centres. Recent data 
showed that other blood sampling time points than C0 may better reflect systemic 
exposure to tacrolimus29-32. In chapter 5 we examined which single time point or 
combination of time points best reflect systemic exposure to tacrolimus, estimating the 
area under the concentration time curve. We calculated limited sampling formulas and 
developed a new and flexible limited sampling model for monitoring tacrolimus 
concentration which is easy to apply in the outpatient clinic, as we did earlier for 
cyclosporine28. 
 
Mycophenolate mofetil (MMF) is increasingly used after OLT, since in contrast to 
calcineurin inhibitors (CNI) like cyclosporine and tacrolimus MMF is not nephrotoxic. It 
may allow CNI reduction or discontinuation, resulting in improvement or stabilization of 
renal function33. Most clinics adhere to a fixed dose of MMF, not based on any individual 
patient or population characteristics34. Recent studies with conflicting results and 
limitations have been performed to explore current evidence and clinical relevance of 
TDM (C0 and limited sampling strategies) of MMF35-40. Limited information on this is 
available in liver transplant patients41-42. In chapter 6 we described the 
pharmacokinetic behaviour of MMF in stable liver transplant patients and looked at 
possible relationships of albumin concentration, creatinine clearance and co-medication 
(especially calcineurin inhibitors) with MPA clearance, the active metabolite of MMF. 
Furthermore we investigated the correlation of C0 with AUC0-12h and possible 
interpatient variability. Finally we developed different limited sampling models for 
implementation of therapeutic drug monitoring of MMF in liver transplant patients, with 
special attention to kidney function in patient selection. 
 
In chapter 7 we summarize the results of our studies and we discuss the possible role 
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Background: After orthotopic liver transplantation (OLT) many patients use emulsified 
cyclosporine. Recent data showed that blood levels 2 hours after dosing (C-2) better 
reflect  systemic exposure to the drug  (area under the blood concentration time curve) 
than trough levels (C-0) do.  
 
Methods: We investigated difference in dosage, creatinine clearance (CrCl), blood 
pressure (BP), freedom from rejection, and relation of C-2, C-0, and AUC while 
switching 31 stable patients more than 6 months after OLT from C-0 to C-2 monitoring. 
With C-0 between 90 and 150 ng/ml we collected 24-hour urine, while blood samples 
were taken at t = 0, 1, 2, 3, 4, 6 and 8 hours after dosing to measure cyclosporine, 
creatinine, liver tests, and blood pressure and calculated AUC and CrCl. Target AUC was 
calculated based on C-0. Then the dose was adjusted to two subsequent C-2 values of 
600 ng/ml ± 15%, the above was repeated, and the differences were assessed.  
 
Results: Cyclosporine dose was reduced in 21/31 patients (68 %) and remained 
unchanged in 10/31 (32%) after conversion. Mean lowering was 69 mg daily (26.9 %, 
P < 0.0001). After dose reduction the mean increase of CrCl was 7.93 ml/min (11.6 %, 
P = 0.016). Only systolic and mean morning BP decreased slightly but significantly. C-2 
correlated better with AUC0-12 (r²=0.75) than C-0 (r²=0.64). However, 13/21 patients 
had a second AUC below target AUC and 2 of these 13 patients developed rejection 
after conversion to C-2 levels.  
 
Conclusion: While C-0 monitoring frequently results in overdosing and more renal 
dysfunction, C-2 monitoring may lead to episodes of underdosing and rejection. 





After orthotopic liver transplantation (OLT) many centers use the microemulsion 
formulation of cyclosporine (Neoral®) as immunosuppressant1. There is a small 
therapeutic window between too low systemic exposure to the drug, resulting in 
rejection, and too high systemic exposure, leading to adverse effects such as renal 
insufficiency and elevated blood pressure. Usually Neoral is given twice daily. Until 
recently dosage was based on trough-level (C-0) monitoring. Recent data, however, 
mostly derived from kidney transplantation but also from heart, lung and liver 
transplantation, show that blood levels 2 hours after dosing (C-2), better than trough 
levels reflect the systemic exposure over the first 12 hours after dosing (= AUC as gold 
standard)2-5. Based on these and other studies it has been recommended that 
monitoring based on trough levels should be replaced by monitoring based on C-2 
levels both for initial therapy and for maintenance tretment6,7. However, only limited 
data have been published on the results of C-2 monitoring in liver transplantation8-15. 
In the present study we investigated the possible influence of the conversion from C-0 
monitoring to C-2 monitoring in stable patients more than 6 months after liver 
transplantation in the dose, creatinine clearance (CrCl), blood pressure, and freedom 
from rejection, with the hypothesis that there was no such influence. Furthermore, we 
calculated the AUC before and after this change in monitoring, and we investigated 




PATIENTS AND METHODS  
 
The study included 31 stable patients who were at least 6 months post-OLT (21 men, 
mean age 52, range 31-64 years; 10 women, mean age 39, range 20-58 years). One 
patient had a biliodigestive (Roux-en-Y) anastomosis, and 30 patients had a duct-to-
duct choledochus anastomosis. All patients received Neoral cyclosporine (Neoral) twice 
daily and were maintained on a stable Neoral dose with two consecutive trough levels 
(C-0) between 90 and 150 ng/ml before entering the study. Co-medication consisted of 
mycophenolate mofetil in 9 patients (4 with prednisone), azathioprine in 8 patients (4 
with prednisone), and prednisone alone in 8 patients; 6 patients had no 
immunosuppressive co-medication. 
During the day of the AUC, 24-hour urine was collected for measurement of creatinine 
concentration. Five minutes before the morning dose (approximately 10:00 AM) of 
Neoral (t = 0), blood samples were taken for liver and kidney function and Neoral 
concentration.  
Further blood samples for Neoral concentration were taken 1, 2, 3, 4, 6 and 8 hours 
after the morning dose of Neoral. For t = 12 we took the trough level (t = 0), because 
all our patients were dosed with Neoral twice daily. Blood was taken using an indwelling 
catheter and was collected in a vacutainer containing EDTA. Whole blood Neoral 
concentrations were determined by Fluorescence Polarisation Immuno Assay (FPIA, 
Axsym, Abbott Diagnostics, Abbott Park, IL). In order to avoid an influence (however 
small) from meals, the patients were instructed to take only a light breakfast with tea 
and a biscuit on the morning of measuring the AUC, and until the 2-hour sample (C-2) 
was taken, the patients took no additional food or drinks16.  Between t = 1 and t = 2 
and between t = 6 and t = 8, blood pressure was measured automatically (Dynamap) 
for one-half hour (morning BP and afternoon BP) with the patient in a reclining chair. 
Then, according to the recommendations by E. Cole et al.6, the dose was adjusted to a 
Neoral level at t = 2 (C-2, peak level) within the target range of 510 and 690 ng/ml 
(600 ± 15%) using the formula: new dose = old dose х (600/ C-2). Two weeks after 
the day the first AUC was measured while on C-0 monitoring ("day 1") and the 
contingent adjustments, the patients came to the clinic for a checkup and a blood 
sample, which was taken exactly two hours after the morning dose of Neoral (C-2). 
Further dose adjustments were made using the same formula within weeks. Blood 
pressure medication was not adjusted during the study. When two subsequent  
C-2-values were within the target-range, patients were invited for a second day, when 
the AUC was measured (“day 2”) similar to the first “AUC-day” (“day 1”). Again 24-hour 
urine was collected for the creatinine concentration and blood samples were taken for 
liver and kidney function tests. The AUC0-12h of all 62 (2 x 31) curves was calculated 
using the trapezoidal rule17, and relationships with C-0 and C-2 were investigated. 
Differences in second and first C-0, C-2 and AUC and their relation, and changes in 
renal function, liver functions, and blood pressure were assessed. The "target AUC 
range" was calculated based on the C-0 range of 90-150 ng/ml, using the linear 
regression line formula describing the relation of C-0 with AUC0-12h. 
 
Statistical Analysis 
Statistical analysis was performed using SPSS 10.0 for Windows (SPSS Inc., Chicago, 
IL). Results are expressed as mean ± SEM and as median and range (Wilcoxon-test). 
Potential differences were explored with Paired-Samples T-test, and relationships were 
investigated using Pearson correlation test and linear regression analysis. P-values less 






Of the 31 patients 21 (68%) needed a lower dose of Neoral when dosing was based on 
C-2 monitoring instead of C-0 monitoring. In 10 patients (32%) no change in the 
dosage of Neoral was necessary and none of the patients required a higher dosage after 
conversion to C-2 monitoring. In patients in whom the dose was lowered, the dose on 
day 2 (median 200 mg, range 150-250 mg) was significantly lower than the dose on 
day 1 (median 250 mg, range 200-350 mg), reduction of 26.9 % of initial dose,  
















Kidney Function and Blood Pressure 
Of the 21 patients whose dose was lowered, we calculated the creatinine clearance 
(CrCl) before (day 1) lowering and after (day 2) lowering of the dose. The mean 
increase of the CrCl in these patients was 7.93 ± 3.0 ml/min (11.6% of initial CrCl,  
P = 0.016, Fig. 2). The change in systolic blood pressure (morning and afternoon) was 
– 4.1 ± 1.6 mmHg and +1.52 ± 1.95 mmHg (– 3.1 % and +1.2%, P = 0.018 and  
P = 0.444). The change in diastolic blood pressure (morning and afternoon) was  
– 1.33 ± 0.98 mmHg and +0.048 mmHg ± 1.26 (–1.6 % and 0.00 %, P = 0.188 and  
P = 0.970). The differences in the mean arterial pressure (morning and afternoon) were 
– 2.62 ± 1.09 mmHg and 0.00 ± 1.52 mmHg (– 2.6 % and 0.00 %, P = 0.026 and  




Estimation of Systemic Exposure (AUC) while on C-2 Monitoring versus AUC 
while on C-0 Monitoring 
C-2 monitoring correlated better (r² = 0.75, Fig. 3) than the C-0 monitoring  
(r² = 0.64, Fig. 4) with the area under the curve (AUC0-12h). The mean AUC on day 1 
was 4588 ± 171 µg.h/L, median 4229 µg.h/L, range 3261–6423 µg.h/L. The mean AUC 
on day 2 was 3210 ± 117 µg.h/L, median 3195 µg.h/L, range 2380-4096 µg.h/L,  
P < 0.0001 (Fig. 5). Figure 6 shows the difference of C-0 values on the first and the 
































C-2 Values on Day 1 and Day 2 in Relation to C2 Target Range 
As mentioned above, while on C-0 monitoring, C-2 was above the target C-2 in  
21/31 patients. In 10/21 patients whose Neoral dose was lowered there were variable 
C-2 levels; C-2 was outside the target range on day 2 with the same dose after two 
subsequent C-2 values of 600 ng/mL ± 15%. Mean C-2 value in the 21 patients whose 
dose was lowered was 666 ± 23 ng/mL (Fig. 7); however, on day 2 just 1/21 of  
C-2-values was below the target range (C-2 = 485ng/mL) and 9/21 were above the  
C-2 target range (mean of these 9: 765 ± 20 ng/mL). Also, 7/10 patients with an 
unchanged Neoral dose had variable C-2 levels with values of C-2 outside the  


















AUC on Day 2 in Relation to Target AUC 
We found that 13/21 patients whose Neoral dose was lowered ended below the  
“target AUC” and were therefore below the lowest exposure on C-0 monitoring. This 
target AUC is based on the C-trough (C-0) and was calculated with linear regression 
analysis (Fig. 4). The formula of the line is: 
AUC0-12h = 14.75 x C-trough + 2053 (trendline).  
The target range of the trough-levels is 90 - 150 ng/mL; therefore, the AUC target 
range is 3380 - 4266 µg.h/L. The other 8/21 patients showed a second AUC within the 
range of the target AUC. As expected, no patient whose Neoral dose was lowered had 
an AUC on day 2 above the highest AUC on day 1.  
 
C-2 and AUC on Day 2 in Relation to Each Other and in Relation to the Target 
Ranges 
Table 1 shows the C-2 and AUC0-12h of Neoral on day 2 in relation to the target ranges 
of C-2 and AUC0-12h in the patients in whom the dose was lowered (n = 21). Mean 
AUC on day 2 was 3543 ± 109 µg.h/L. Of those patients in whom the Neoral dose was 
lowered and whose second AUC was below the target AUC, 2/13 developed acute 
cellular rejection with aminotransferases up to 500 U/L, requiring additional 
corticosteroids and an increase in Neoral dose after the second AUC. These 2 patients 
were 9 and 10 months after OLT; both had prednisone as co-medication and one also 
had mycophenolate mofetil (MMF) as co-medication. Of the 31 patients, 4 were within  
6 - 12 months after OLT; the low AUCs were not limited to these 4 patients. However, 










In order to reach the subsequent C-2 values of 600 ng/mL ± 15 %, we needed  
1.57 ± 0.19 (median 1.00; range 1-3) dose adjustments. Patients with the peak level 
at 1 hour after dosing had an AUC within the target range as often as did patients with 
the peak level at 2 hours post-dosing. Table 2 shows the C-2 and AUC0-12h of Neoral 
on day 2 in relation to the target ranges of C-2 and AUC0-12h in the patients whose 












Differences between Subgroups of Patients 
Because only 1 patient with a hepaticojejunostomy was included, no differences 
between this patient and the other 30 with a duct-to-duct anastomosis could be 
assessed. No differences in C-2 or AUC of patients with different immunosuppressive 
co-medications were found, although the number of patients is too small to reliably 
assess differences between these groups. 
 
Sparse Sampling and AUC0-12h 
If AUC is calculated, using the trapezoidal rule, from cyclosporine levels on time points 





During the conversion from C-0 to C-2 cyclosporine monitoring in stable patients more 
than 6 months after liver transplantation, we saw a significant decrease in cyclosporine 
dose in two-thirds and an unchanged dose in one-third of the patients. Dose reduction 
resulted in lower systemic exposure and an improvement of renal function, but only 
small changes in morning systolic and mean morning blood pressures were observed, 
with questionable clinical significance. The fact that the kidney function did not improve 
in all patients may be due to long-term exposure to Neoral, which may have caused a 
fixed renal insufficiency. Also, further improvement in renal function may require more 
time. Based on calculating the area under the curve from 0 to 12 hours (cyclosporine 
blood levels), the correlation of C-2 with AUC was better than the correlation of C-0 
with AUC from 0-12 hours. However, in almost one-half of the patients, there was 
significant intrapatient variability of the C-2 blood levels with the same dose. This made 
therapeutic drug monitoring with C-2 levels less accurate and may induce many 
unnecessary subsequent changes in drug dose, which is inconvenient for patients, 
doctors, and nurses. We found it disturbing that, although two preceding C-2 levels 
were within the 600 ng/mL ± 15% range, in 13/21 patients whose dose was lowered 
the second AUC was below the target AUC, while indeed 2 of these 13 patients 
developed rejection. The fact that these patients were 9 and 10 months post OLT may 
mean that the dose recommendations of G. Levy and not those of E. Cole should be 
followed when using C-2 monitoring6,7. Further investigations assessing this point may 
be needed. While on C-2 monitoring, 17/31 patients had a second AUC outside the 
target AUC. For all patients it may not be necessary to have an AUC within the range of 
the “target range AUC”, but it certainly seems safer if this is the case. Probably the best 
situation is to have an AUC on day 2 in the lower half of first AUCs, which is  
3380 – 3823 µg.h/L. Because 11/13 patients with a second AUC below the target AUC 
did not develop rejection, some patients may tolerate lower AUCs.  
Other studies saw a better correlation of C-2 with AUC when compared to trough-level 
monitoring in renal and liver graft recipients3-15. Most studies in renal transplantation 
and the limited studies in liver transplantation using C-2 monitoring also showed 
improved kidney function, and often blood pressure and serum cholesterol also 
improved. In those studies no rejection occurred despite lower exposure to 
cyclosporine. However, in the liver transplant studies mentioned AUC was calculated by 
measuring Neoral blood levels during 4 and 6 hours only, while we used 0-12 hour 
AUCs. This fact may explain part of the difference between these and our studies. 
Another explanation may be the lower maintenance levels used in liver transplantation 
when compared to kidney transplantation: further lowering of the dose may more easily 
lead to rejection. All samples were taken as recommended6,7,18 and within 2 minutes 
from the targeted time (although 10 minutes are allowed); if sampling time would have 
been more variable (as may be the case in daily practice), an even lower accuracy of  
C-2 monitoring and inappropriate dose adjustments might occur19. In renal 
transplantation variable cyclosporine levels may contribute to chronic rejection20. 
Although chronic ductopenic rejection has become less common after liver 
transplantation in the past decade, it forms a continuum with acute cellular rejection; 
chronic underexposure to cyclosporine can be a cause21-24. In renal transplant studies it 
was shown that absorption profiling over the first 4 hours was superior to trough-level 
monitoring, with C-2 as the best single-point predictor of AUC3,25-28. The clinical 
superiority of such absorption profiling over C-2 levels has not been examined in those 
studies. Our data demonstrate that in stable liver transplant patients trough-level 
monitoring frequently leads to overdosing of cyclosporine, while monitoring by C-2 may 
cause episodes of underdosing. Therefore, better ways of monitoring cyclosporine 
dosing in liver transplantation remain to be devised. Because both IL2 blood 
concentration and 12-hour AUC are related to cyclosporine exposure in the first 4 hours 
after dosing it seems logical to use a sparse-sampling method over the first hours after 
dosing. In accordance with others, our data demonstrate that, if AUC is calculated from 
cyclosporine levels, using the trapezoidal rule, in the first three hours after dosing the 
correlation with AUC0-12h is 0.96
25, 29. Thus use of this method may avoid over- and 
underdosing and unnecessary changes in dose. A disadvantage is the need for fixed 
time points. The ideal model should be easy to use and flexible, without the rigid time 
points used in current multiple-sampling methods, and it should be based both on 
population kinetics and on individual pharmacokinetics30-34.  We are currently 
developing such a model. 
In conclusion, while C-0 monitoring frequently results in overdosing and more renal 
dysfunction, C-2 monitoring may lead to episodes of underdosing and rejection. 
Therefore, better ways of monitoring cyclosporine dosing need to be devised. 
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Background: New methods to estimate the systemic exposure to ciclosporin such as the 
level 2 h after dosing and limited sampling formulas may lead to improved clinical 
outcome after orthotopic liver transplantation. However, most strategies are 
characterized by rigid sampling times.  
Aim: To develop and validate a flexible individualized population-pharmacokinetic model 
for ciclosporin monitoring in orthotopic liver transplantation.  
Methods: A total of 62 curves obtained from 31 patients at least 0.5 year after 
orthotopic liver transplantation were divided into two equal groups. From 31 curves, 
relatively simple limited sampling formulas were derived using multiple regression 
analysis, while using pharmacokinetic software a two-compartment population-
pharmacokinetic model was derived from these same data. We then tested the ability to 
estimate the AUC by the limited sampling formulas and a different approach using 
several limited sampling strategies on the other 31 curves. The new approach consists 
of individualizing the mean a priori population-pharmacokinetic parameters of the two-
compartment population-pharmacokinetic model by means of maximum a posteriori 
Bayesian fitting with individual data leading to an individualized population-
pharmacokinetic limited sampling model. From the individualized pharmacokinetic 
parameters, AUC0-12h was calculated for each combination of measured blood 
concentrations. The calculated AUC0-12h both from the limited-sampling formulas and 
the limited-sampling model were compared with the gold standard AUC0-12h 
(trapezoidal rule) by Pearson‟s correlation coefficient and prediction precision and bias 
were calculated.  
Results: The AUC0-12h value calculated by individualizing the population-
pharmacokinetic model using several combinations of measured blood concentrations:  
0 + 2 h (r² = 0.94), 0 + 1 + 2 h (r² = 0.94), 0 + 1 + 3 h (r² = 0.92), 0 + 2 + 3 h  
(r² = 0.92) and 0 + 1 + 2 + 3 h (r² = 0.96) had excellent correlation with AUC0-12h, 
better than limited sampling formulas with less than three sampling time points. Even 
trough level with limited sampling method (r² = 0.86) correlated better than the level 
after 2 h of dosing (r² = 0.75) or trough level (r² = 0.64) as single values without 
limited sampling method. Moreover, the individualized population-pharmacokinetic 
model had a low prediction bias and excellent precision.  
Conclusion: Multiple rigid sampling time points limit the use of limited sampling 
formulas. The major advantage of the Bayesian estimation approach presented here, is 
that blood sampling time points are not fixed, as long as sampling time is known. The 
predictive performance of this new approach is superior to trough level and that after  
2 h of dosing and at least as good as limited sampling formulas. It is of clear advantage 
in busy outpatient clinics. 
INTRODUCTION 
 
After orthotopic liver transplantation (OLT), generally, the microemulsion formulation of 
ciclosporin (Neoral) (CYCLO) is used as the immunosuppressant1. There is a small 
therapeutic window between too low a systemic exposure to the drug resulting in 
rejection on the one hand and, too high a systemic exposure, leading to adverse effects 
like renal insufficiency and elevated blood pressure on the other. Usually CYCLO is 
given twice daily. Until recently, dosage was based on trough-level (C-0) monitoring. 
Recent data, however – mostly derived from kidney transplantation but also from heart, 
lung and liver transplantation – show that blood levels 2 h after dosing (C-2) reflect the 
systemic exposure over the first 12 h after dosing (AUC as gold standard), better than 
trough levels2–5. Based on these and other studies, it has been recommended to replace 
monitoring based on trough levels by the one based on C-2 levels both for initial 
therapy and for maintenance treatment6,7. However, only limited data have been 
published on the results of C-2 monitoring in liver transplantation8–14. We recently 
reported that C-0 monitoring resulted in overdosing in two-thirds of the patients, while 
conversion to C-2 monitoring may lead to episodes of underdosing and rejection, 
although the average kidney function improved15. In the current study, we develop and 
validate an easy-to-apply limited sampling method (LSM) based on an individualized 
Bayesian population-pharmacokinetic (POP-PK) model for monitoring CYCLO dosing 
after liver transplantation, integrating all available information. In contrast to previously 
published Bayesian methods and limited sampling formulas (LSFs), sampling times are 
less fixed in our individualized POP-PK model. 
 
 
PATIENTS AND METHODS 
 
Thirty-one stable patients who were at least 6 months post-OLT (21 men, mean age  
52 years, range 31–64; 10 women, mean age 39 years, range 20–58) were included. 
One patient had a biliodigestive (Roux-en-Y) anastomosis, and 30 had duct-to-duct 
choledochal anastomoses. All patients received Neoral (CYCLO; Novartis, Basel, 
Switzerland) twice daily and were maintained on a stable CYCLO dose with two 
consecutive trough levels (C-0) between 90 and 150 µg/L before entering the study. 
Co-medication consisted of mycophenolate mofetil in nine patients (four with 
prednisone), azathioprine in eight patients (four with prednisone), prednisone alone in 
eight patients, while six patients had no immunosuppressive co-medication. Five 
minutes before the morning dose (approximately 10:00 hours) of CYCLO (t = 0), blood 
samples were analysed for liver and kidney function and CYCLO concentration. Further 
blood samples for CYCLO concentration were taken 1, 2, 3, 4, 6 and 8 h after the 
morning dose of CYCLO. For t = 12, we took the trough level (t = 0), as all our patients 
were treated with CYCLO twice daily. We previously determined that concentrations at  
0 and 12 h were equal in these patients. Blood was taken using an indwelling catheter 
and was collected in a vacutainer containing ethylenediaminetetraacetic acid (EDTA). 
Whole-blood CYCLO concentrations were determined by fluorescence polarization 
immunoassay (FPIA, Axsym; Abbott Diagnostics, Abbott Park, IL, USA). In order to 
avoid an influence (however small) of meals, the patients were instructed to take only a 
light breakfast with tea and a biscuit on the morning of measuring the AUC, and until 
the 2-h sample (C-2) was taken, the patients took no additional food or drinks16. The 
blood pressure was measured once in the morning and once in the afternoon for half an 
hour. Then, according to the recommendations by Cole et al6. the dose was adjusted to 
a CYCLO level at t = 2 (C-2, peak level) within the target range of 510 and 690 µg/L 
(600 ± 15%) using the formula: new dose = old dose * (600/C-2). Two weeks after the 
day the first AUC was measured while on C-0 monitoring (day 1) and the contingent 
adjustments the patients came to the clinic for checkup and a blood sample was taken 
exactly 2 h after the morning dose of CYCLO (C-2). Further dose adjustments were 
made within weeks using the same formula. When two subsequent C-2 values were 
within the target range, patients were invited for a second AUC measurement (day 2) 
similar to the first „AUC day‟ (day 1). The „gold standard‟ AUC0-12h of all 62 (2 х 31) 
curves was calculated using the trapezoidal rule17. Relationships with C-0 and C-2 were 
investigated. Differences in second and first C-0, C-2 and AUC and their relation, and 
changes in renal function, liver functions and blood pressure were assessed. The „target 
AUC range‟ was calculated based on the C-0 range of 90–150 µg/L, using the linear 
regression line formula describing the relation of C-0 with AUC0-12h for all 62 curves.  
 
Development of limited sampling methods 
We sorted the 62 curves using AUC and divided them into two groups of 31 curves, 
based on almost similar values of the AUCs. One group of 31 curves was used for 
calculation of LSFs and for the development of a POP-PK model with a priori POP-PK 
parameters. This POP-PK model after individualization was also termed as limited 
sampling model (LSM). The second group of 31 curves was used for validation of the 
POP-PK model. 
 
Calculation of limited sampling formulas 
Using multiple regression analysis, simple LSFs were calculated from 31 curves based 
on one or a combination of measured blood concentrations. Their ability to estimate the 
AUC was tested on the remaining 31 curves. The formulas for 0 h; 1 h; 2 h; 3 h;  
0 + 1 h; 0 + 2 h; 0 + 3 h; 0 + 1 + 2 h; 0 + 1 + 3 h; 0 + 2 + 3 h; and 0 + 1 + 2 + 3 h 











A priori POP-PK parameters 
Using the Kinpop module of the pharmacokinetic software package MW\Pharm version 
3.33 (Mediware, Groningen, the Netherlands), a population two-compartment model 
(POP-PK model) with a lag-time and first-order absorption pharmacokinetics was 
calculated from the CYCLO dosing, body weight and the blood concentration values of 
the 31 curves. This program uses an iterative two-stage Bayesian procedure, and 
calculates mean, median and standard deviation values of the pharmacokinetic 
parameters18. During the iterative two-stage Bayesian procedure, pharmacokinetic 
parameters were set to be distributed log-normally, and bioavailability was fixed at 0.5. 
A POP-PK model was calculated using the 31 blood concentration–time curves. This a 
priori model acts as a starting point to calculate values for each patient from the 
available patient-specific data and the a priori population model, leading towards an 
individualized PK model, indicated as an a posteriori model. The population model is the 
PK model based on many measurements in many patients. Combination of the POP-PK 
model with a limited number of CYCLO blood levels (limited sampling) of each individual 
patient together with clinical parameters from the same patient (weight, drug dosing, 
dosing interval, time between dosing and sampling) yields an a posteriori individualized 
patient-specific pharmacokinetic LSM. Therefore, each patient has his or her specific 










A posteriori pharmacokinetic parameters of the individual patients 
The calculated mean POP-PK parameters were individualized for each of the remaining 
31 AUCs based on their CYCLO dosing and weight and one or a combination of 
measured blood concentrations (0 h; 1 h; 2 h; 3 h; 0 + 1 h; 0 + 2 h; 0 + 3 h;  
0 + 1 + 2 h; 0 + 1 + 3 h; 0 + 2 + 3 h; 0 + 1 + 2 + 3 h) according to the maximum a 
posteriori (MAP) Bayesian fitting method using the MW\Pharm computer program19. 
Fitting any available information, i.e. a priori population parameters, patient weight, 
drug dosage regimen, and measured blood concentrations by means of MAP Bayesian 
method, we estimated the a posteriori pharmacokinetic parameters of the individual 
patients. These a posteriori pharmacokinetic parameters of the individual patients are 
the maximum-likelihood estimates obtained by MAP Bayesian fitting, minimizing the 
deviations of measured and predicted concentrations, and of POP-PK parameters and 
pharmacokinetic parameters of the individual patient19. This LSM approach is very 
flexible and it ensures an optimal use of available information, both from a population 
and from the individual patient. From these individualized pharmacokinetic parameters 
the area under the CYCLO blood concentration–time curve (AUC0-12h) was calculated 
for each combination of measured blood concentrations. The individualized POP-PK 
model (LSM) was assessed with several single points of blood sampling and also with 
different combinations of serial measurements. We compared the various models and 
verified the correlation of the models with the gold standard AUC0-12h in the second 
set of 31 curves. 
 
Statistics 
Statistical analysis on patient data was performed using SPSS 10.0 for Windows (SPSS 
Inc., Chicago, IL, USA). Results are expressed as mean ± S.E.M. and as median and 
range (Wilcoxon test). Potential differences were explored with paired-samples t-test, 
and relationships were investigated using Pearson correlation test and linear regression 
analysis. P-values below 0.05 were considered statistically significant. The AUCs 
calculated by different methods were compared with the gold standard AUC0-12h by 
linear regression and Pearson correlation coefficient. Predictive performance of the 
different methods was also investigated by calculating the prediction precision and bias 
according to Sheiner and Beal20. Prediction bias was calculated as the mean prediction 
error (MPE), that is the mean of differences between the AUC0-12h according to the 
different methods and the gold standard AUC0-12h. Prediction precision was calculated 
as the mean absolute prediction error (MAPE), that is the mean of the absolute 
differences between the AUC0-12h according to the several different methods and the 
gold standard AUC0-12h. Smaller values for MPE and MAPE indicate less bias and 





The results of conversion from C-0 to C-2 monitoring after OLT as far as dose 
adjustments, renal function, blood pressure, rejection and CYCLO C-0, C-2 levels and 
AUCs have been reported elsewhere15. The dose was lowered in 68% of the patients 
(reduction of 26.9% of initial dose; P < 0.0001) and remained unchanged in 32% of the 
patients after conversion from C-0 to C-2 monitoring. For those patients whose CYCLO 
dose was lowered, the mean increase of the creatinine clearance (CRCL) was  
7.93 ± 3.0 mL/min (11.6% of initial CRCL; P = 0.016). After CYCLO dose lowering 
blood pressure changes were minimal, blood pressure changes were minimal, with only 
a significant improvement for systolic and mean blood pressure in the morning. 
Thirteen of 21 patients whose CYCLO dose was lowered ended below the „target AUC‟, 
and hence below the lowest exposure on C-0 monitoring. This target AUC is based on 
the trough level (C-0) and was calculated with linear regression analysis. The formula of 
the line is: AUC0-12h = 14.75 * C-trough + 2053 (trend-line). The target range of the 
trough levels is 90–150 µg/L, and hence the AUC target range was originally defined as 
3380–4266 h*µg/L15. Eight of 21 patients showed a second AUC within the range of 
target AUC. Two of 13 patients in whom the CYCLO dose was lowered and whose 
second AUC was below the target AUC developed acute cellular rejection with 
aminotransferases up to 500 U/L, requiring additional corticosteroids and an increase in 
CYCLO dose after the second AUC (AUCs were 2684 and 3075 h*µg/L, respectively). 
Significant changes in C-2 were observed intra-individually with the same dose. 
 
Calculation of LSFs 
Using multiple regression analysis, LSFs were calculated from 31 curves based on one 
or a combination of measured blood concentrations. Our results and those from 
previous studies with Bayesian models indicate the best correlation with the gold 
standard when the first 3 h after dosing are included and with multiple sampling points 
when the trough level is included. These results (0 h; 1 h; 2 h; 3 h; 0 + 1 h; 0 + 2 h;  
0 + 3 h; 0 + 1 + 2 h; 0 + 1 + 3 h; 0 + 2 + 3 h; 0 + 1 + 2 + 3 h) are shown in Table 1.  
 
A priori POP-PK parameters 
The mean POP-PK parameters of the 31 curves of „group 1‟ was calculated by an 
iterative two-stage Bayesian procedure, and their standard deviations are shown in 
Table 2. 
 
A posteriori pharmacokinetic parameters of the individual patients 
Table 3 shows the correlation with the gold standard AUC0-12h, the MPE and MAPE for 
one-point sampling; one- and multiple-point sampling with MAP Bayesian fitting 
procedure using the individualized POP-PK model (LSM); and one and multiple-point 
sampling using the LSFs. AUCs calculated by individualizing the POP-PK model yielding 
an individualized LSM based on the combinations of measured blood concentrations:  
0 + 2 h (r² = 0.94), 0 + 1 + 2 h (r² = 0.94) (Figure 1), 0 + 1 + 3 h (r² = 0.92)  
(Figure 2), 0 + 2 + 3 h (r² = 0.92) and 0 + 1 + 2 + 3 h (r² = 0.96) (Figure 3) had 
excellent correlation with AUC0-12h. Most models without C-0 had r² below 0.90 (data 
not shown). Precision and bias were within acceptable ranges (≤ 10) provided that C-0 
with or without one or more additional blood samples was taken in combination with 






























In the current study we developed a new, accurate, flexible and precise method for 
CYCLO monitoring in stable patients more than 6 months after liver transplantation 
based on an individualized limited sampling POP-PK model. This contrasts to most 
current LSMs that are only based on population pharmacokinetics. Our PK model is 
based on population pharmacokinetics and Bayesian fitting of limited sampling data 
from one patient. The method with 0 + 2, 0 + 1 + 2, 0 + 1 + 3, 0 + 2 + 3 or  
0 + 1 + 2 + 3 h sampling showed excellent correlation with the gold standard  
12-h AUC. Results even for C-0 combined with the model were better than those for 
simple C-0 or C-2. A major advantage of the new method over current methods based 
on population kinetics only, such as LSFs, is that sampling time points are more flexible 
than with, e.g. C-2 monitoring, LSFs or current POP-PK models. Our model is efficient 
as long as the exact dosing and sampling time, the weight of the patient and the dosing 
rhythm are registered and sampling time is near the required time after dosing. Both 
population and individual kinetics are incorporated in our new PK model, making 
optimal use of available information. Blood concentration data are put into the 
computer model, which runs on a desktop PC, and the AUC is calculated and a dose 
modification suggested. It is still necessary to obtain more than one blood 
concentration of CYCLO during the dosing interval in order to obtain adequate estimates 
(>90%) of AUC0-12h. While this might be possible in an in-patient setting, applying 
this method to out-patient practice may be considered difficult and impractical for both 
the patient and provider. However, as our results show, the correlation with AUC0-12h 
of the individualized POP-PK model is better than with LSFs, especially when less than 
three sampling points were used, e.g. when the combination of C-0 and C-2 or the 
combination of C-0, C-1 and C-2 were taken. The R² for C-2 was below 0.80 even with 
individualized POP-PK model or LSF. The individualized POP-PK model correlated very 
well (>0.90) with AUC0-12h even with only two time points for 0 + 2 h, and with three 
sampling points for 0 + 1 + 2, 0 + 1 + 3 and 0 + 2 + 3 h. Indeed, time C-0 almost 
always needed to be included for a correlation >0.90. These sampling times were less 
fixed than in LSFs where they need to be exactly on time (otherwise the model is not 
valid). When, for example, C-1 is forgotten, but C-0, C-2 and C-3 are obtained, 
individualized POP-PK model can be used with excellent correlation with AUC. Using an 
individualized POP-PK model with multiple sampling points requires some organization 
in the clinic but in our experience this is feasible and the advantages are clear. It might 
be possible to reduce the number of samplings per visit and the number of visits to the 
clinic in stable patients in the long term and still get sufficient prediction of AUC, but 
this requires further study. Our current data show that our individualized POP-PK model 
using multiple sampling points is superior to the other methods.  
The clinical consequences of the improved prediction require further evaluation. 
Conversion of monitoring CYCLO more than 6 months after OLT from C-0 towards C-2 
resulted in dose reduction in two-thirds of the patients, which was associated with 
improved renal function and marginal improvement in blood pressure. However, 
significant intrapatient variability of the C-2 blood levels with the same dose and AUCs 
below the target range in more than half of the patients whose dose was lowered 
occurred with C-2 monitoring, sometimes resulting in rejection. This was reflected in a 
R² value of only 0.75 for C-2 compared with AUC0-12h (Table 3), which limits the 
accuracy of therapeutic drug monitoring with C-2 levels and may induce many 
unnecessary subsequent changes in drug dose, which is inconvenient for the patients, 
doctors and nurses. Based on the current POP-PK model and generally accepted trough 
levels of 90–125 µg/L, the AUC range should be 2900–3800 h*µg/L, a range we now 
adhere to in our clinic, although we cannot exclude that some patients may tolerate 
lower values. While correlation of C-2 with AUC is better than that of C-0 with AUC, it is 
far from perfect. Others observed a better correlation of C-2 with AUC when compared 
with trough-level monitoring in renal and liver graft recipients3–6. Most studies in renal 
transplantation and the limited studies in liver transplantation using C-2 monitoring also 
showed improved kidney function, and often blood pressure and serum cholesterol also 
improved. In those studies, no rejection occurred despite lower exposure to CYCLO 
than while on C-0 monitoring. However, in the reported liver transplant studies, AUC 
was calculated by measuring CYCLO blood levels during 4 and 6 h only, while we used 
0–12 h AUCs. This may explain part of the difference between these and our  
studies7–14. Another explanation may be the lower maintenance levels used in liver 
transplantation when compared with kidney transplantation; further lowering of the 
dose may more easily lead to rejection. All samples were taken as recommended6,7,21 
and within 2 min from the target time (although 10 min were allowed for C-2); if 
sampling time would have been more variable (as may be the case in daily practice) 
this would have led to an even lower accuracy of C-2 monitoring and inappropriate dose 
adjustments22. This may also be true for LSFs or POP-PK models with fixed sampling 
time points. In renal transplantation, variable CYCLO levels may contribute to chronic 
rejection23. Although chronic ductopenic rejection has become less common after liver 
transplantation in the last decade, it forms a continuum with acute cellular rejection 
and chronic underexposure to CYCLO can be a cause24–27. In renal transplant studies it 
was shown that absorption profiling over the first 4 h was superior to trough level 
monitoring, with C-2 as the best single-point predictor of AUC3,12,28–31. The clinical 
superiority of such absorption profiling over C-2 levels has not been examined in those 
studies. Our data demonstrated that in stable liver transplant patients trough level 
monitoring frequently leads to overdosing of CYCLO, while monitoring by C-2 may 
cause episodes of underdosing15. According to Levy and Cole the long-term benefits of 
reduced toxicity caused by C-2 monitoring might well outweigh the development of 
mild, easily treated rejection32. However, it may be better to try to avoid these 
rejections as well as toxicity. Therefore, better ways of monitoring CYCLO dosing in 
liver transplantation are required. 
As both blood interleukin (IL)-2 concentration and 12-h AUC are related to CYCLO 
exposure in the first 4 h after dosing, it seems logical to use a sparse-sampling method 
in the first hours after dosing33,34. It had already been shown that using multiple 
sampling points in the first hours after dosing with Bayesian forecasting results in a 
better correlation with AUC0-12h35–38. A high inter-individual variability in CYCLO 
pharmacokinetics exists, which seems unrelated to CYP3A polymorphisms39. Therefore, 
the use of multiple sampling models may avoid over- and underdosing and unnecessary 
changes in dose. A disadvantage of available LSFs and POP-PK models was that 
multiple samplings were needed on fixed time points. It was previously stated that the 
ideal model should be easy to use and flexible, without the rigid time points and 
complicated methods used in current multiple sampling models, and it should be based 
both on population kinetics and on individual pharmacokinetics37,38,40,41. The LSM 
presented in the current study clearly approximates this goal. A similar model 
performed well in kidney as well as combined kidney– pancreas transplant patients42. 
However, the effect of its use on clinical outcome remains to be investigated. As our 
liver LSM model was developed in stable liver transplant patients, it also needs to be 
evaluated whether graft dysfunction affects the model. We anticipate that use of our 
model (even with only C-0) will lead to a more stable CYCLO dose with less over- or 
underdosing than with simple C-0 or C-2 monitoring. Whether this leads to less 
rejection or renal insufficiency needs to be determined. In conclusion, while C-0 
monitoring frequently results in overdosing and more renal dysfunction, C-2 monitoring 
may lead to episodes of underdosing and rejection and many subsequent dose 
adjustments. We therefore devised a flexible Bayesian individualized limited sampling 
POP-PK model for CYCLO monitoring without rigid sampling time points, which is 
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Background: We recently developed and validated limited sampling models (LSMs) for 
cyclosporine monitoring after orthotopic liver transplantation based on individualized 
population pharmacokinetic models with Bayesian modelling. 
 
Aim: To evaluate LSM in practice, and to seek optimal balance between benefit and 
discomfort. 
 
Methods: In 30 stable patients, more than 6 months after orthotopic liver 
transplantation, previously switched from trough- to 2 h post-dose (C2)-monitoring, we 
switched to 3-monthly LSM 0,1,2,3 h-monitoring. During 18 months we evaluated dose, 
creatinine clearance, calculated area under the curve, intra-patient pharmacokinetic 
variability and ability to assess systemic exposure by several previously validated LSMs. 
 
Results: Within patients, there was variability of cyclosporine-area under the curve with 
the same dose (CV of 15%). Compared to C2-monitoring, there was no significant 
difference in dose (P = 0.237), creatinine clearance (P = 0.071) and number of 
rejections. Some models showed excellent correlation and precision with LSM 0,1,2,3 h 
comparing area under the curves (0,2 h: r2 = 0.88; 0,1,3 h: r2 = 0.91; 0,2,3 h: 
r2 = 0.92, all P < 0.001) with no difference in advised dose. 
 
Conclusion: The limited sampling model, with only trough- and 2-h sampling, yields 
excellent accuracy and assesses systemic exposure much better than C2 with less bias 
and greater precision. Considering the calculated intra-patient variability, more 




Calcineurin inhibitors like cyclosporine are frequently used after solid organ 
transplantation such as orthotopic liver transplantation (OLT). However, these drugs 
are characterized by a narrow therapeutic range with risks of overdosing and 
underdosing. For this reason systemic exposure of this drug is routinely assessed. 
Several methods with varying complexity and performance exist. Until recently most 
clinics used trough-level monitoring (C0) to assess systemic exposure to cyclosporine, 
but over the last years many centres replaced this method by so-called C2-monitoring, 
where blood samples were taken exactly 2 h after oral administration of the drug1-10. 
This method has been shown superior in predicting the area under the curve (AUC) and 
toxicity. In a previous study, in stable patients more than 6 months after OLT, we 
demonstrated lowering of the dose in two-thirds of the patients with improved kidney 
function when switching from C0- to C2-monitoring11. However, a substantial 
percentage of underdosing occurred with this method, suggesting the need for even 
better monitoring methods. 
We then developed and validated flexible limited sampling models (LSMs), based on an 
individualized population pharmacokinetic (PK) model, limited sampling and Bayesian 
estimations, which was again superior to C2.12 All patients who were previously 
switched from C0- to C2- cyclosporine monitoring were now switched to 3-monthly 
monitoring with this LSM and followed for a period of 18 months. This strategy allowed 
us to investigate the feasibility of implementation of LSM into daily practice, and the 
potential effects of the change from C2 to LSM on such factors as dose, renal function, 
rejection rate and also interpatient variability. Using LSM, it was possible to determine 
intra-patient variability in PK of cyclosporine. With this, it was possible to determine the 
required precision of the method used. In addition, a new target range for cyclosporine 
AUC based on the 95% confidence interval for clearance could be calculated. 
 
 
PATIENT AND METHODS 
 
Thirty stable patients more than 1 year after OLT (20 men, mean age 54, range 34–66; 
10 women, mean age 42, range 22–61) received the micro-emulsion formulation of 
cyclosporine (Neoral; Novartis Pharmaceuticals, Basel, Switzerland) twice daily as 
immunosuppressant. The reasons for OLT were cirrhosis due to hepatitis B-virus (four 
patients), alcoholic liver disease (seven patients), primary biliary cirrhosis (one 
patient), hepatitis C-virus (five patients), primary sclerosing cholangitis (one patient), 
Budd Chiari syndrome (two patients), autoimmune-hepatitis (one patient), Wilson‟s 
disease (two patients), hepatocellular carcinoma (three patients), neuroendocrine 
tumour (one patient), acute fatty liver of pregnancy (one patient) and two patients with 
acute liver failure with unknown aetiology. 
During the study, one patient sometimes had aminotransferases just above the upper 
limit of normal, probably as signs of reactivation of hepatitis C-virus, but this was not 
the case on a 3-monthly cyclosporine monitoring day. No cases of hematuria or 
proteinuria occurred. The mean time of exposure to cyclosporine prior to entry in this 
study was 46 ± 26 months (range 12–109). Six patients showed rejections between the 
time of OLT and time of starting this study, but all were stable again when entering the 
study. 
After informed consent, the patients came to the clinic for check-up and blood samples 
were taken for cyclosporine concentration close to 0 h, 1 h, 2 h and 3 h after the 
morning dose of cyclosporine, while still on C2- monitoring. Whole blood cyclosporine 
concentrations were determined by Fluorescence Polarisation Immuno Assay  
(FPIA, Axsym; Abbott Diagnostics, Abbott Park, IL, USA). 
Then cyclosporine dose was adjusted based on AUC calculation of LSM 0,1,2,3 h12. 
AUCs were calculated using the following formula:  
AUC = (F_po * dose * 1000) / clearance, in which F_po is the bioavailability which is 
fixed at 0.5 for cyclosporine micro-emulsion, dose is the morning dose of cyclosporine 
and clearance is the clearance of cyclosporine calculated for the combination of time 
points 0 + 1 + 2 + 3 h using the PK software package MW\Pharm version 3.50 
(Mediware, Groningen, The Netherlands)13.  
After every limited sampling curve, a dose advice was given using the formula: 
Advised dose = (target AUC / calculated AUC) * dose, in which 3350 is set as value for 
the target AUC [middle of target-range, (2900 + 3800) / 2], which is based on the 
range of trough-level monitoring of 90–125 μg/L11. If allowed by renal function  
(CRCL > 50 mL/min) the dose was adjusted to the advised dose. Every 3 months 
thereafter LSM 0,1,2,3 h was obtained and cyclosporine dose adjusted accordingly. 
After dose adjustment an extra curve was obtained. From the 30 patients in total  
152 LSM 0,1,2,3 h-curves (mean per patient 5 ± 2, range 1–9) were collected over the 
last 18 months. Four patients changed to other immunosuppressive medication during 
the course of this study (one because of rejection, two because of renal dysfunction, 
one because of gum hyperplasia). 
Blood samples were also taken for kidney- and liver function. Creatinine clearance 
(CRCL) was calculated with Cockcroft & Gault formula. As warranted by our liver 
transplant protocol, a liver biopsy was obtained when rejection was suspected. 
Moderate-to-severe rejection was treated with additional immune suppression, while in 
mild rejection the dose of maintenance immune suppression was optimized. 
Intra-patient variability in clearance (CV%) was investigated calculating the mean and 
standard deviation of the clearance of all curves for all patients using the formula: 
variation coefficient = (standard deviation / mean clearance) * 100%.  
In order to create a new target-range for the AUC, a 95% confidence interval for 
clearance was calculated using the formula: 
AUC = (0.5*dose*1000) / (clearance ± 2s.d.) 
 
Statistics 
Statistical analysis on patient data was performed using SPSS 11.0.1 for Windows 
(SPSS Inc., Chicago, IL, USA). Results are expressed as mean ± s.d. and as median 
and range. Potential differences were explored with Paired Samples t-test and 
relationships were investigated using Pearson correlation test and Pearson chi-squared 
test. P-values below 0.05 were considered to be statistically significant. AUCs were 
calculated using previously developed and validated LSMs12.  
The calculated AUCs, based on a single-point and combinations of blood sampling time 
points, were compared with the AUC based on time points 0 + 1 + 2 + 3 h by Pearson 
correlation test. Predictive performance of this method was also investigated by 
calculating the prediction precision and bias according to procedures developed by 
Sheiner and Beal14. Prediction bias was calculated as the mean prediction error (MPE), 
this is the mean of differences between the AUCs of the different models and the AUC 
based on time points 0 + 1+2 + 3 h. Prediction precision was calculated as the mean 
absolute prediction error (MAPE), this is the mean of the absolute differences between 
the AUCs of the different models and the AUC based on time points 0 + 1 + 2 + 3 h. 
Smaller values for MPE and MAPE indicate less bias and greater precision (acceptable 





Time to reach peak concentration 
While monitoring cyclosporine concentration in blood there was a difference between 
patients and also within patients concerning the time to reach peak concentration of 
cyclosporine. From all the 152 curves we obtained, there were 69 curves (45%) with a 
peak on C1, 71 curves (47%) on C2 and 12 curves (8%) on C3 (Table 1). Table 2 
shows a few examples of the results per patient demonstrating considerable intra-
patient variability. 
Based on these results we may conclude that monitoring only on C2 is not reflecting the 



















Variation of clearance 
Calculating the variation coefficient (CV%) for every patient using the mean clearance 
and standard deviation of all curves this CV% was 15%. Mean dose of all patients was 
109 mg twice daily, so natural variation in one patient is 109*0.15 = 16 mg. 
We calculated a 95% confidence interval for the clearance in order to create a new 
target range, which is based on natural variation. This new target range is  
2380–4390 h*μg/L, much wider than the target range we use in our clinic  
(2900–3800 h*μg/L). Even when we use 1s.d. instead of 2s.d. the target range would 
be 2680–3620 h*μg/L. 
 
Difference in dose, kidney function and rejection 
Before switching from C2-monitoring to LSM 0,1,2,3 h mean cyclosporine dose, while 
on C2-monitoring, was 207 ± 9 mg daily (range 150–350 mg). After switching, mean 
daily dose was 218 ± 10 mg (range 100–300 mg). Mean change in dose was 11 ± 9 mg 
(P = 0.237, median 0.0, range −100 to +100), so there was no significant change of 
average cyclosporine dose after switching from C2-monitoring to LSM 0,1,2,3 h. 
Looking at the individual patient, only two patients once had a daily-dose change of 
100 mg, one −100 mg and one +100 mg. The other patients had daily-dose changes of 
50 mg or less. 
Mean CRCL on C2-monitoring was 77.0 ± 4.5 mL/min (range 40.4–132 mL/min). While 
using LSM 0,1,2,3 h mean CRCL was 73.0 ± 4.8 mL/min (range 26.6–128.8 mL/min). 
The difference in CRCL between C2-monitoring and LSM 0,1,2,3 h was 
−4.0 ± 2.1 mL/min (P = 0.071) so on average there was no significant change of the 
kidney function. Looking at the individual patient level, there was a wide variability in 
CRCL change (range: –30.1 to +17.7, median: −5.4). Even when dividing all patients 
into three groups (tertiles) based on CRCL in each group there was a comparable 
variability of CRCL (data not shown). 
While using LSM 0,1,2,3 h for 18 months, there were two moderate-to-severe 
rejections vs. two moderate-to-severe rejections during the previous 18 months on  
C2-monitoring. 
 
Correlation of other LSMs with LSM 0,1,2,3 h 
For the LSM 0,1,2,3 h model and for the models with time points 0 h, 1 h, 2 h and 3 h 
and the combinations of time points 0,1 h, 0,2 h, 0,3 h, 1,2 h, 1,3 h, 2,3 h, 0,1,2 h, 
0,1,3 h, 0,2,3 h and 1,2,3 h we calculated for all 152 curves the AUC and the 
correlation with LSM 0,1,2,3 h (Table 3). Correlation of AUC calculated with LSM 
0,1,2,3 h for other multiple-point models was much better than LSM 0 h and LSM 2 h. 
Two 2-point-models showed good correlation with our 0,1,2,3 h model:  
LSM 0,2 h (r2 = 0.88) and LSM 0,3 h (r2 = 0.87) with acceptable bias and precision. 
Three 3-point-models also showed good correlation with acceptable bias and precision: 
LSM 0,1,2 h (r2 = 0.84), LSM 0,1,3 h (r2 = 0.91) and LSM 0,2,3 h (r2 = 0.92)  
(Figure 1). Of special interest is the important contribution of the trough-level (C0), 
which seems to be indispensable for adequate monitoring of cyclosporine in 












































We then calculated the correlation of these five two-point and three-point LSMs with 
LSM 0,1,2,3 h per patient. Looking only at the 20 patients with at least five 0,1,2,3 h 
curves, in 19/20 patients we see a high and significant correlation of AUCs calculated 
with LSM 0,1,2,3 h and those AUCs calculated with the models LSM 0,2 h, LSM 0,1,2 h, 
LSM 0,1,3 h and LSM 0,2,3 h. For the LSM 0,3 h in 16/20 patients there was a good 









These correlations suggest that these other LSMs with less time points show results 
comparable to LSM 0,1,2,3 h and that particularly LSM 0,2 h is an accurate, reliable and 
very practical model with acceptable bias and precision for monitoring cyclosporine, as 






This study, in the first place, shows that it is feasible to implement cyclosporine 
monitoring based on limited sampling and an individualized population PK model in a 
liver transplant out-patient clinic. 
Second, we show that cyclosporine dose, renal function and rejection rate did not 
change significantly after our switch from C2-based monitoring to LSM 0,1,2,3 h. Third, 
we show that often we decided not to increase the cyclosporine dose because of renal 
dysfunction while we were advised to do so because the calculated AUC was below the 
target range, while usually no rejection followed. This means that apparently the lower 
limit of the target range was too high. Fourth, a significant intra-patient variation 
appeared to occur with the same cyclosporine dose. Fifth, several two- and three-point 
– previously validated- LSMs correlated very well with the four-point LSM 0,1,2,3 h. All 
include the trough level, which seems indispensable to get an accurate AUC prediction, 
as we previously showed. Sixth, the LSM 0,2 h seems optimal in terms of accuracy, 
ease-of-use and intra-patient variability. 
Because of the narrow therapeutic range of cyclosporine, assessing the systemic 
exposure to this drug is mandatory. Ideally, a full AUC is measured on a regular basis. 
As this is not practical and C0 is a rough estimation of the AUC, for many years 
monitoring based on trough levels was used. Then many centers switched to monitoring 
based on C2, after it was shown that C2 correlates better with AUC as Citerrio describes 
in an article about the evolution of the therapeutic drug monitoring of cyclosporine15. 
This had the disadvantage of a fixed time point after dosing, which is difficult for some 
patients. Moreover, C2 still does not reflect very well the AUC and according to the 
review study of Marin et al. the best way to individualize therapy is still controversial. 
Recommendations are made for clinical research that could be done to provide more 
definitive evidence for the use of C2 or other limited sampling strategies16. After  
C0-monitoring and the more precise C2-monitoring we showed that our  
LSM 0,1,2,3 h-method more accurately estimates systemic exposure to cyclosporine in 
OLT patients, based on limited sampling, individualized population PK models and 
Bayesian estimations with an easy-to-use computer model12. LSMs have the advantage 
that sampling times are not rigid in contrast to most limited sampling strategies 
described in a review article of David and Johnston17. Switching from C0- via  
C2-monitoring and subsequently to LSM 0,1,2,3 allowed us to compare the biochemical 
and clinical effects of these three methods. 
There appeared to be considerable intra-patient variability of time to reach the peak-
concentration of cyclosporine. This led to the same number of dose adjustments as with 
C2-monitoring in the 18 months before the C2 to LSM 0,1,2,3 h switch. The intra-
patient PK variability may partially be due to interaction with food or other medication. 
The variation in peak-time is partially responsible for the large intra-patient variation in 
C2 levels over time in some of the patients. With an LSM with more sampling time 
points, all important information required for calculating an AUC is obtained and the 
chance of „missing‟ this variability is less, which leads to more accurate AUC 
estimations. 
After more than one-and-a-half-year of using our model for cyclosporine monitoring in 
the out-patient clinic, 152 LSM 0,1,2,3 h curves from 30 patients were derived. 
Although this is not a randomized controlled trial these stable patients were their own 
controls. According to the dose, renal function and rejection on average there was no 
difference using C2-monitoring or the individualized PK model. However, the target 
range was based on AUCs while on C0-monitoring. In an earlier study, while on C2-
monitoring, we saw two rejections in 13 cases where the AUC dropped below the AUC 
target range. Apparently, an AUC below 2900 h*μg/L is tolerated in many patients. This 
was similar for LSM 0,1,2,3 h monitoring: for some patients the dose was not increased 
as advised after LSM 0,1,2,3 because renal insufficiency did not allow us to do so, but 
although these patients were at risk of underdosing, usually no signs of rejection 
occurred. 
Although there was no significant change in CRCL between C2-monitoring and  
LSM 0,1,2,3 h, there seemed to be a trend toward lower CRCL with LSM vs.  
C2-monitoring (P = 0.071). More data is needed to confirm the usefulness of tailoring 
cyclosporine dosing by LSM to minimize toxicity. 
The current data allow us to investigate the true natural variability in PK of cyclosporine 
in stable OLT patients. The mean intra-patient variability of the apparent oral clearance 
of cyclosporine in these stable liver transplantation patients was 15%. This means that 
a dose adjustment of 16 mg or less (15% of mean dose of 109 mg) is not rational, 
because this difference is a natural variation, which cannot be avoided. In fact, the 
lowest possible dose adjustment (25 mg) in practice is relatively close to this natural 
variation of 16 mg. In case the mean dose of 109 mg and a 95% confidence interval 
(mean ± 2*s.d.) would be used, a target range of 2380–4390 h*μg/L would be 
rational. In other words, any AUC value within this range can be explained by natural 
variability in PK of cyclosporine and may therefore not require a dose adjustment.  
In our hospital, a target range of 2900–3800 h*μg/L was used for stable OLT patients, 
which is narrower, and closer to a mean ± 1*s.d. value of the AUC in this population, 
which is 2680–3620 h*μg/L. However, to be on the safe side, we until now remain 
adhering to this narrow range, although we realize that this may be too strict. Based on 
the current data, a lower range for the AUC than currently used with a target AUC of 
2830 h*μg/L (2380–3280 h*μg/L) may be reasonable. 
Our data suggest that, considering the natural variability in PK of cyclosporine in stable 
OLT patients, our method with LSM 0,1,2,3 h may be too accurate in terms of 
estimating systemic exposure to cyclosporine. 
When investigating the correlation between LSMs with only two or three sampling 
points and the LSM 0,1,2,3 h we see that overall five models showed good correlation 
when considering both the AUCs and the mean advised dose. These five LSMs were 
0,2 h; 0,3 h; 0,1,2 h; 0,1,3 h and 0,2,3 h. Accuracy and bias were acceptable. The 
trough level is included into all of these models, which illustrates the pivotal role of this 
sample for assessing systemic exposure to cyclosporine. We are aware of the fact that 
these five models are abbreviated curves from the already abbreviated 0,1,2,3 h curve, 
but recently we already noticed a very good correlation of these models with the gold 
standard AUC0–12 h (for LSM 0,2 h this was: r
2 = 0.94, MPE = −9, MAPE = 9) with less 
bias and greater precision than e.g. C2 single-point monitoring (r2 = 0.78, MPE = −10, 
MAPE = 12) or Ctrough12.  
In spite of the fact that LSM 0,1,2 h includes both the common 1- and 2-h peak-level 
time points, the correlation of this model with LSM 0,1,2,3 h in the patients with five or 
more curves is not different from LSM 0,2 h (r2 =  0.84–1.00 vs. 0.81–0.99). 
Comparing LSM 0,1,2 h with LSM 0,2 h, the 0,2 h-model has the benefit that it is easier 
to apply in practice, it is more friendly for the patient and the medical staff, and there is 
a cost-benefit. Therefore this model seems an optimal balance between benefit and 
discomfort for the patient. A large randomized controlled trial between C2 and LSM 
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Background: Trough (C0) monitoring is not optimal for therapeutic drug monitoring of 
tacrolimus. To better estimate systemic exposure of tacrolimus and achieve clinical 
benefit, an improved therapeutic drug monitoring strategy should be developed.  
 
Methods: The authors examined which single and combination of time points best 
estimated the empiric “gold standard” AUC0-12h and developed and validated a new, 
flexible, and accurate limited sampling model for monitoring tacrolimus in patients 
having undergone liver transplantation. Twenty-three stable patients with full AUC0-12h 
were divided into two groups based on area under the concentration-time curve/dose. 
With multiple regression analysis, limited sampling formulae were derived and 
population-pharmacokinetic-based limited sampling models were developed and 
validated. A regression analysis was performed between either area under the 
concentration-time curves calculated with formulae or models with the reference 
trapezoidal AUC0-12h.  
 
Results: Both formulae and models based on single samples C4-C6  
(r2 = 0.94 [MPE/MAPE 0/7]-0.90 [2/8] and 0.97 [0/7]-0.97 [1/5]) showed excellent 
performance. The calculated area under the concentration-time curve target range for 
tacrolimus was 90 to 130 h*µg/L. Multiple point sampling performed better, especially 
when using models (r2 > 0.94). C0 was a less precise predictor of AUC0-12h compared 
with both formulae and models (r2's 0.68 [5/17] and 0.87 [2/14]).  
 
Conclusion: Trough concentration monitoring is not an accurate method for assessing 
systemic exposure to tacrolimus in stable patients having undergone liver 
transplantation. This new limited sampling model, based on single time points C4-C6, 




The calcineurin inhibitor tacrolimus is widely used for immunosuppression after 
orthotopic liver transplantation (OLT). Tacrolimus has a small therapeutic window, 
underexposure can result in rejection whereas overexposure can lead to adverse 
effects, especially nephrotoxicity. Accurate monitoring of this drug is therefore 
mandatory to improve clinical outcome1,2. For cyclosporine, another calcineurin 
inhibitor, different methods have been developed to estimate systemic exposure using 
the area under the concentration-time curve (AUC), which can result in better clinical 
outcome in terms of reduction of toxicity and improved renal function3-13.   
Monitoring tacrolimus (FK-506, Prograf Astellas Pharma, Stainer, UK) therapy is still 
based on trough concentration (C0) monitoring in most centers. However, recent data 
have shown that C0 does not accurately reflect systemic exposure over the first  
12 hours after dosing14. Patients with similar C0 tacrolimus concentrations can have 
very different AUCs. Other studies in liver and kidney transplantation have suggested 
different time points at which better predictions of systemic exposure of tacrolimus can 
be made than using trough concentrations14-17.  
When better prediction of total systemic exposure of tacrolimus in the first 12 hours 
after dosing is possible, we may see improved clinical outcome in terms of fewer 
rejection episodes and lowering of toxicity. 
The aim of the present study was to examine which single time point or combination of 
time points best reflect systemic exposure of tacrolimus by calculating the area under 
the curve and then to develop and validate a new, flexible, and accurate limited 
sampling model, which is easy to apply in clinical practice as we have shown previously 
for cyclosporine18,19.  
 
 
PATIENTS AND METHODS 
 
Twenty-three stable patients having undergone liver transplantation from Leiden 
University Medical Center, who were at least 6 months post-OLT (11 men, mean age  
45 years, range 31-73 years; 12 women, mean age 44 years, range 21-70 years) were 
included. Twenty-two patients received tacrolimus (Astellas Pharma Inc., Deerfield, IL) 
twice daily and one patient only once daily 0.5 mg in the morning. Mean morning 
tacrolimus dose was 3.0 ± 0.35 mg (range, 0.50-8.00 mg). In our liver transplant 
clinic, trough concentration monitoring is used with a target range of 5 to 10 µg/L for 
patients more than 3 months after OLT20.  
All patients provided informed consent and the study was approved by the Medical 
Ethical Committee of the Medical Center. Stable patients having undergone liver 
transplantation were selected and visited our clinic for 1 day. The patients had no 
infections or other complications and were not receiving any interacting comedication. 
Specifically, bilirubin and albumin levels were not outside clinical reference ranges. 
Five minutes before taking the morning dose of tacrolimus (approximately 10:00 AM), 
blood samples were taken for liver and kidney function and tacrolimus (C0) 
concentration. The patients were instructed to take their evening dose of tacrolimus the 
night before the morning of the study visit at 10:00 pm. Further blood samples for 
tacrolimus concentration were collected at 1, 2, 3, 4, 6, and 8 hours after 
administration of the morning dose of tacrolimus. Because these were stable patients, 
the C12h concentration was taken to be the same as the C0h, assuming steady-state 
conditions17. It was checked by interview that there were no dose changes in the 
previous week. Blood was drawn using an indwelling catheter and collected in a 
Vacutainer (Becton Dickinson Diagnostics, Franklin Lakes, NJ) containing EDTA. Whole 
blood tacrolimus concentrations were determined by Microparticle Enzyme Immuno 
Assay (IMx; Abbott Diagnostics, Abbott Park, IL). To lower the influence of meals, the 
patients were instructed to take only a light breakfast-tea and a biscuit-on the morning 
the AUC was measured, and until the 2 hours sample (C2), no additional food or drinks 
were taken21.  
AUC0-12h of all 23 curves were calculated with the trapezoidal rule using the software 
package MW\Pharm version 3.60 (Mediware, Groningen, The Netherlands)22,23. The 
patients were assigned to a group on the basis of a climbing AUC/dose ratio in a 1:1 
fashion. Starting with a low ratio, the first patient entered one group and the second 
patient entered the other group until all patients were divided among the two groups. 
Therewith, two groups with a comparable clearance distribution were formed: group 1 
(n = 11) and group 2 (n = 12). Data from group 1 were used to calculate limited 
sampling formulae (LSF) and for the development of a population pharmacokinetic 
(POP-PK) model. Data from group 2 were used to validate this POP-PK model. 
The POP-PK model integrated all available information obtained from PK sampling and 
generated a population model. This model was used to obtain individualized 
pharmacokinetic parameters (individualized PK model based on Bayesian fitting) on the 
basis of new PK information (samples at single or multiple time points) from new 
patients, allowing individualized dose advice to be given. This Bayesian approach is a 
flexible alternative to methods using limited sampling formulae that have fixed 
sampling times24.  
Several single blood sampling time points (C0, C1, C2, C3, C4, C6, and C8) and 
combinations of these samples were examined, 23 in total. We compared the 
performance of limited sampling models (LSM) with the more rigid limited sampling 
formulae. Finally, we performed a validation step and calculated a new target range as 
a basis for future implementation in clinical practice. 
Limited Sampling Formulae 
Using multiple regression analysis (SPSS software; SPSS Inc., Chicago, IL) for group 1, 
relatively simple limited sampling formulae (linear functions) were calculated based on 
one sample or a combination of measured blood concentrations: 0 h, 1 h, 2 h, 3 h, 4 h, 
6 h, 8 h, 0 + 1 h, 0 + 2 h, 0 + 3 h, 0 + 1 + 2 h, 0 + 1 + 3 h, 0 + 2 + 3 h,  
0 + 1 + 2 + 3 h, 1 + 3 h, 1 + 4 h, 2 + 3 h, 2 + 4 h, 2 + 3 + 4 h, 3 + 4 h, 3 + 4 + 6 h, 
3 + 6 h, and 4 + 6 h. Their ability to estimate the AUC was tested on group 2. 
 
Limited Sampling Models  
Using the “Kinpop module” of MW\Pharm, a population two-compartment model with 
first-order absorption pharmacokinetics and without a lag time was calculated from the 
tacrolimus dosing, body weight, and blood concentration values of group 1. This 
program uses an iterative two-stage Bayesian procedure and calculates means, 
medians, and standard deviations of the pharmacokinetic parameters25. During this 
procedure, pharmacokinetic parameters were set to be distributed log-normally, and 
bioavailability was fixed for tacrolimus at 0.23 as a result of the absence of intravenous 
data and on the basis of literature values26.  
The calculated mean POP-PK parameters based on group 1 were individualized for the 
12 patients of group 2 based on tacrolimus dosing and weight and one or a combination 
of measured blood concentration as mentioned for LSF.  
AUCs (µg/L*h) for group 2 were calculated using the following formula: 
AUC = (F_po * dose * 1000) / clearance in which F_po is bioavailability, which is fixed 
at 0.23 for tacrolimus, the dose (mg) is the morning dose of tacrolimus, and clearance 
(L/h) is the clearance of tacrolimus calculated for any of the 12 patients of group 2 for 
each time point or combinations of time points as for LSF (Figure 1). 
Finally, a regression analysis was performed for both the LSF and the LSM with the 














Statistical analysis of patient data was performed using SPSS 13.0 for Windows. Results 
are expressed as mean ± standard deviation and as median and range.  
AUCs calculated by the different methods were compared with the trapezoidal 
calculated AUC0-12h by linear regression analysis (MW\Pharm) and Pearson correlation 
coefficient. P values below 0.05 were considered statistically significant. 
Predictive performance of the different methods was also investigated by calculating the 
prediction precision and bias, which is deduced from the paper by Sheiner and Beal27. 
Prediction bias was calculated as the mean prediction error (MPE), that is the mean of 
differences between the AUC0-12h according to the different methods and the gold 
standard AUC0-12h. Prediction precision was calculated as the mean absolute prediction 
error (MAPE), that is the mean of the absolute differences between AUC0-12h according 
to the different methods and the gold standard AUC0-12h. Smaller values for MPE and 
MAPE indicate less bias and greater precision (practical clinical range based on smallest 





Using multiple regression analysis, LSFs were calculated from 11 curves (group 1) 
based on one or a combination of measured blood concentrations. A few examples are 
shown in Table 1. The results of the performance in estimating the gold standard  













































The best single point markers for tacrolimus monitoring in terms of predicting systemic 
exposure (gold standard AUC0-12h) to tacrolimus using LSF were C4  
(r2 = 0.94 [MPE/MAPE 0/7]), C6 (r2 = 0.90 [2/8]), and C8 (r2 = 0.93 [2/8]), all  
P < 0.05. 
Precise multiple-point combinations using LSF were, for example, C1 + C4  
(r2 = 0.96 [0/5]), C0 + C2 + C3 (r2 = 0.95 [1-6]), and C0 + C1 + C3 (r2 = 0.98 [0/4]), 
all P < 0.05. 
The calculated mean POP-PK parameters based on group 1 are shown in Table 3. The 
upper part of Table 2 shows the performance of the individualized POP-PK model (LSM) 
in estimating the gold standard AUC0-12h, the MPE and MAPE for single- and multiple-















The best single point samples in terms of estimating systemic tacrolimus exposure 
using LSM appeared to be C4 and C6, which show excellent performance with the gold 
standard AUC0-12h (both r
2 = 0.97, P < 0.05) with excellent precision and bias 






















Except for LSM 0 + 1 h, all examined multiple-point LSMs showed excellent 
performance in estimating the gold standard AUC0-12h (Table 2; r
2 = 0.94 or higher,  
not all data shown). 
The widely used C0 showed poorer performance with the gold standard AUC0-12h both 
for LSF and LSM (r2 = 0.68 and 0.87). More importantly, prediction precision for both 
methods was relatively high (MAPE 17% and 14%). Without using a model or formula, 
the r2 of C0 with AUC0-12h was 0.69. 
Based on the C0 target range of 5 to 10 µg/L for patients more than 3 months after 
OLT, we calculated an AUC target range with the use of the pharmacokinetic software 
package MW\Pharm. This range is 95 to 190 h*µg/L (target = [95 + 190]/2 =  
142.5 h*µg/L). 
The range can also be derived from Figure 3. This figure visualizes the relationship 
between the tacrolimus trough concentrations and AUC for this population of patients 
undergoing OLT. A wide range of AUC values is observed corresponding to the  
C0 monitoring range of 5 to 10 µg/L. 
From this figure, possible other (lower) AUC target ranges can be deduced from trough 

























In this study, we demonstrated that C0 monitoring for tacrolimus after liver 
transplantation is not precise and does not accurately reflect systemic exposure. We 
developed and validated individualized POP-PK models based on C4 or C6, which appear 
to accurately reflect systemic exposure of tacrolimus with excellent precision and bias. 
Recent studies on tacrolimus monitoring have suggested that trough concentrations, as 
currently used in most centers for therapeutic drug monitoring of tacrolimus, are not 
the best estimators of systemic exposure of this drug. These studies have involved 
different types of organ transplantation and vary in time after transplantation28-30. In 
our study, C0 monitoring did not have a good performance in estimating AUC0-12h 
without using LSF and LSM (r2 = 0.69), or with using LSF (r2 = 0.68 [MPE/MAPE 5/17]). 
Performance of C0 with AUC0-12h using LSM seems to be acceptable (r
2 = 0.87), but 
concentrating on MPE and MAPE, we conclude that the prediction precision (MAPE) is 
not in an acceptable range of ± 10% (MAPE 14%). Figure 3, which illustrates all  
23 patients while on C0 monitoring, already showed a wide range of AUC values 
corresponding to the (currently accepted) C0 range of 5 to 10 µg/L. This confirms that 
trough concentrations do not adequately reflect systemic exposure of tacrolimus. Our 
finding that sampling between 4 and 6 hours postdosing seems optimal is in line with 
two other studies that suggested C4 and C5 sampling, respectively15,16. Our model has 
the advantage that it is very flexible. Others also found C0 insufficient in different 
patient populations16,17. Likewise, in cyclosporine monitoring, C0 and even  
C2 monitoring did not appear to be optimal, and several methods for optimizing 
therapeutic drug monitoring were developed by our group and others3,6,7,13,19. 
A limitation of our models and formulae is that these were developed and validated in 
two small independent groups of stable patients more than 6 months after liver 
transplantation. Given the considerable changes in tacrolimus kinetics shortly after 
transplantation, we cannot recommend using these models in less stable patients or 
early posttransplantation. For the period early after OLT, new models would need to be 
developed and validated. 
The results concerning correlation with AUC0-12h for both LSF and LSM were satisfying 
with slightly better results for the model. The advantage of this model over LSF is that 
the model is flexible and no fixed time points are needed in contrast to the rigid 
formulae. As long as the exact time of blood sampling is noted, it is possible to use this 
time (and blood concentration) in the model as a result of the fact that this approach is 
based on Bayesian estimation. The AUC is calculated after estimating the individual 
clearance and dose advice is given. 
Comparing single and multiple point monitoring, the latter group showed, in most 
cases, a slightly better performance in estimating AUC0-12h.  
However, despite this slightly better performance, LSM C4 and LSM C6 already had  
r2's of 0.97 (MPE/MAPE 0/7 and 1/5). Therefore, these single point LSMs seem 
sufficient. For practical reasons, both the C4 and the C6 model seem feasible. Patients 
can take their medication at home, visit the hospital for checkups, and blood can be 
drawn 4 to 6 hours after the morning dose, not interrupting the medication schedule. 
There is no need to take the blood sample exactly on time as long as the dosing and 
blood sampling time are recorded. These factors, in combination with the adequate 
performance of the model in the outpatient setting, which is normally a source of 
variability, provides a tool for adequate monitoring of tacrolimus. 
The calculated AUC target range based on C0 monitoring (90-195 h*µg/L) is rather 
wide, which also suggests that C0 monitoring is not the optimal way for therapeutic 
drug monitoring of tacrolimus. In kidney transplantation in our clinic, for stable 
patients, a target AUC of 125 h*µg/L is adhered to (range, 100-150 h*µg/L), 
corresponding to a trough concentration of 7.5 µg/L17.  
Currently, in the field of OLT, a trend with regard to reduction in calcineurin inhibition is 
noticeable. In a review article from Staatz et al, lower targets are described for liver 
transplantation compared with kidney transplantation31. With respect to this trend, and 
after observing Figure 3, we decided to adopt a new target, slightly lower than used for 
kidney transplantation, in the stable period more than 6 weeks posttransplantation17 
and also lower than the range corresponding with C0 = 5 to 10 µg/L, which we were 
using in our clinic. 
Thus, for the last 6 months, we have lowered the C0 range from 5 to 10 µg/L to the 
arbitrary range of 4 to 8 µg/L, which is 80% of the original range, without rejection 
(data not shown). We now calculate a new AUC target and AUC target range, which is 
80% of the original AUC target (142.5 µg/L) and which is based on the lowest possible 
dose adjustment of 0.5 mg, which would be, respectively, 110 h*µg/L for the target 
and 90 to 130 h*µg/L for the range. The new target AUC of 110 h*µg/L is based on the 
C0 concentration of (4 + 8)/2 = 6 µg/L. The new range (90-130 h*µg/L) is wider than 
the lowest possible dose adjustment of 0.5 mg, which makes it practical in daily use. 
The new target is visualized in Figure 3 and the clinical consequences will be studied 
prospectively. 
The current trend toward lower target ranges underlines the need for precise 
monitoring, because tacrolimus underexposure should be avoided with respect to the 
prevention of rejection episodes. High tacrolimus exposure should be avoided as well, 
especially in the stable phase post-OLT, with regard to clinical toxicity such as 
nephrotoxicity, which could have a clear negative impact on patient and graft 
survival1,2. 
With more accurate prediction of systemic exposure of tacrolimus in the first 12 hours 
after dosing with the individualized LSMs C4 or C6, we have developed we expect 
improvement in clinical outcome such as decrease in rejection rate, less 
(nephro)toxicity, and fewer infections. We are planning further validation with a 
prospective, randomized, controlled trial comparing C0 and LSM 4 h (or 6 h) 
monitoring, which includes clinical outcome parameters such as renal function, blood 
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Background: The immunosuppressive drug mycophenolate mofetil (MMF), with 
mycophenolic acid (MPA) as active metabolite, is a non-nephrotoxic alternative to 
calcineurin inhibitors in liver transplant patients. Limited data is available of therapeutic 
drug monitoring strategies for MMF. Monitoring MMF becomes even more relevant in 
preventing rejection in CNI-free regimens. We aimed to describe the pharmacokinetic 
(PK) behaviour of MMF in different immunosuppressive regimens to develop a 
monitoring strategy for MMF.  
 
Methods: PK data were obtained from stable patients (n=34) and the effect of 
covariates (liver and kidney function, serum albumin concentration) and CNI  
co-medication on PK-parameters was studied. A TDM-strategy was developed based on 
Bayesian estimations, limited sampling models and immunosuppressive co-medication.  
 
Results: A linear relationship between MMF-dose and MPA-AUC was found and a  
7-fold apparent clearance range was observed. Significant relationships of albumin 
concentration and creatinine clearance with MPA-plasma clearance were identified 
(r²=0.26, r²=0.36; p<0.05). The model 0+½+1+2h shows good correlation with 
trapezoidal-AUC0-12h with acceptable bias and precision (with CNI: r²=0.82,  
without CNI: r²=0.85; p<0.05).  
 
Conclusion: This study demonstrates the large variability of MPA in liver 
transplantation, the association of albumin and creatinine clearance with this 
variability, and illustrates the use of population based monitoring strategies ranked to 







Mycophenolate mofetil (MMF) is the 2-morpholinoethyl ester of mycophenolic acid 
(MPA), an immunosuppressive agent. MPA is an inosine monophosphate dehydrogenase 
(IMPDH) inhibitor and therefore inhibits the de novo pathway of guanosine nucleotide 
synthesis and thus the proliferative responses of T- and B-lymphocytes1. 
MMF is widely used as immunosuppressant after different types of organ 
transplantation including liver transplantation (LT). It is often administered in 
combination with a calcineurin inhibitor (CNI), tacrolimus (TRL) or cyclosporine (CsA), 
but also without CNI in order to spare renal function, since MMF is not nephrotoxic. Use 
of MMF may allow CNI dose reduction or discontinuation, with improvement or 
stabilization of renal function2. 
Different studies in the past years, most in renal and cardiac transplant patients, 
showed a significant inverse correlation between MPA exposure and the risk of acute 
rejection3-6. Fewer studies were performed in liver transplant patients. Generally, 
results in terms of patient and graft survival are good if used in combination with a CNI, 
but a switch to MMF monotherapy after LT can be associated with a rate of 0-20% 
acute cellular rejection which – if not treated adequately – can lead to chronic rejection 
and graft loss7. However, rejection rates of 10% or more have been reported in  
MMF-monotherapy after liver transplantation, which may be related to low exposure of 
MPA8-11. 
In contrast to therapeutic drug monitoring (TDM) for CNIs, at this moment most clinics 
adhere to a fixed dose of MMF, not based on any individual patient characteristics like 
age, weight, MPA- or creatinine clearance12. Recently, studies have been performed to 
explore current evidence on the usefulness and clinical relevance of MPA trough level 
monitoring during MMF therapy in solid organ transplantation13-14. Also several limited 
sampling strategies have been proposed and studied mostly in renal transplant 
patients, with often 3-5 sampling time points taken in the first 2-6 hours after  
dosing15-17. Le Guellec et al. developed a limited sampling strategy based on Bayesian 
estimations as a tool for therapeutic drug monitoring in renal transplant patients18. 
However, there is limited information on TDM of MPA in liver transplant patients19,20. 
This becomes even more relevant in CNI free regimens. 
Therefore the aim of this study was to describe the pharmacokinetic (PK) behaviour of 
MPA in liver transplant patients in the context of different co-immunosuppression (with 
or without CNI). In addition we were aiming at estimating inter-patient variability of 
MPA clearance in order to develop a TDM-strategy using flexible limited sampling 
models (LSM) for MPA. We studied factors (covariates) like albumin concentration and 
creatinine clearance that could have an effect on MPA pharmacokinetics. 
 
MATERIALS AND METHODS 
 
Thirty-four stable patients using MMF who were at least 3 months after OLT were 
included (median 214 weeks, range 16-630). Apart from MMF seven patients received 
tacrolimus (± prednisone) as co-medication, fifteen received cyclosporine  
(± prednisone), and twelve patients received only glucocorticoids (11 prednisone,  
1 budesonide) next to MMF. So, 22 patients were on CNI co-medication and 12 patients 
were without CNI co-medication. Table 1 shows the patients characteristics for different 

















 mean S.D. mean S.D. mean S.D. mean S.D. P 
Age (years) 49 12 54 6 50 12 39 16 0.063 
Dose twice 
daily (mg) 
720 287 875 311 633 248 643 244 0.085 
Weight (kg) 77 19 75 15 78 21 77 22 0.981 
Albumine 
(g/L) 
41.5 3.7 42.1 3.2 41.8 3.0 39.9 5.6 0.751 
CRCL(mL/min) 72 31 57 31 72 29 96 25 0.032* 
Table 1: Patient characteristics of all patients for different groups of co-medication (without CNI; CsA 
(cyclosporine) and TRL (tacrolimus)). P-values indicate the level of significance of differences between 
the 3 groups (non-parametric Kruskal-Wallis-test, *=significant).  
 
Mycophenolate mofetil (CellCept®, Roche, Basel, Switzerland) was given twice daily. In 
our clinic MMF-dosing for liver transplant patients was based on fixed dose regimens. 
Patients started with 500 mg twice daily and if allowed by absence of leuco- and 
trombopenia and gastrointestinal side-effects the dose was increased to and kept at 
1000 mg twice daily. In three cases a deviant dose of twice daily 250 mg (1 patient), 
750 mg (1 patient) or 1500 mg (1 patient) was given. 
After informed consent, all patients visited our clinic for one day. Five minutes before 
administration of the morning dose of MMF (approximately 10.00h AM) blood samples 
were obtained for liver and kidney function, serum albumin concentration and MPA (C0) 
concentration. Creatinine clearance (CRCL) was calculated with Cockcroft and Gault 
formula. Patients were instructed to take their evening dose the night before their visit 
at 10.00h PM. Further blood samples for MPA concentration were collected at  
0.5, 1, 2, 3, 4 and 6 hours after administration of the morning dose of MMF. The 
missing C=12h was obtained by extrapolation from t=0h to t=12h, assuming steady 
state condition.  
Blood was drawn using an indwelling catheter and collected in a vacutainer containing 
EDTA. Plasma MPA concentrations were determined using High Performance Liquid 
Chromatography (HPLC)43. In order to lower possible influence from meals the patients 
were instructed to take only a light breakfast - tea and a biscuit - on the morning of 
measuring the AUC, and until the 2 hours sample (C2) no additional food or drinks were 
taken.  
Population pharmacokinetic (POP-PK) limited sampling models were developed using 
the kinpop module of MW\Pharm, version 3.60 (Mediware, Groningen, the 
Netherlands)21. An oral 2-compartment model with first order absorption and lag-time 
described the data adequately. The best models were selected, based on the log-
likelihood-value of MW\Pharm, the correlation with trapezoidal MPA-AUC and precision 
and bias. A trapezoidal AUC0-12h of all 34 curves was calculated with the trapezoidal 
rule, using the software package MW\Pharm. 
Individualized PK parameters (individualized PK-model based on Bayesian fitting,  
i.e. post hoc values) were obtained. AUCs (mg.h/L) based on MPA clearance on single 
blood sampling time points and combinations of time points were calculated based on 
the formula: AUC = (F_po * dose) / clearance, in which F_po is bioavailability which 
was fixed to 1 for MMF since no i.v. data were available31. The dose (mg) is the 
morning dose of MMF and clearance (L/h) became apparent clearance (CL/F) of MPA in 
the absence of information on bioavailability. CL/F was estimated for all patients with 
Bayesian estimation at different time points and combinations of time points  
(limited sampling models).  
 
Statistics 
Statistical analysis on patient data was performed using SPSS 13.0 for Windows  
(SPSS Inc., Chicago, IL, USA). Results are expressed as mean ± S.D. and as median 
and range. Potential differences in patient characteristics were tested with non-
parametric Kruskal-Wallis-test. 
AUCs calculated with the formula AUC = dose / clearance were compared to the 
trapezoidal AUC0-12h with Pearson correlation coefficient. P-values below 0.05 were 
considered statistically significant. 
The ability to describe the trapezoidal AUC0-12h of the different methods was also 
investigated by calculating the prediction precision and bias deducted from the paper of 
Sheiner and Beal22. Prediction bias was calculated as the mean prediction error (MPE); 
that is the mean of differences between AUC0-12h calculated with the formula shown 
above and the trapezoidal AUC0-12h. Prediction precision was calculated as the mean 
absolute prediction error (MAPE); that is the mean of the absolute differences between 
the calculated AUC0-12h and the trapezoidal AUC0-12h. Smaller values for MPE and 






There was a linear relationship between MMF dose and trapezoidal MPA area under the 
curve (Figure 1). There was a wide range in MPA clearance (apparent clearance =  
Cl/F = dose/AUCtrap) in the population (8.08 – 57.47 L/h). Dividing the total population 
into 3 groups based on co-medication, the MPA clearance ranges are 8.08 – 31.55 L/h 
for patients without CNI, 8.27 – 57.47 L/h for those on cyclosporine and 13.66 – 43.10 

















Figure 1: MMF dose versus trapezoidal MPA-AUC relationship of patients with MMF dose 500 mg and 
1000 mg twice daily (n=31, dose 500 mg: n=18; dose 1000 mg: n=13) 
 
Looking at possible sources of this variability in MPA clearance, there appeared to be a 
significant inverse relationship between serum albumin concentration and MPA 
clearance (r² = 0.26, p<0.05). Specifically, low albumin levels are related to higher 
MPA clearance. There also was a significant relationship between creatinine clearance 
and MPA clearance (r² = 0.36, p<0.05). No significant difference in CRCL existed 
between the two groups with and without calcineurin inhibitors, data not shown. 
Co-medication 
To explore potential differences in (dose adjusted) MPA-AUC between patients with 
different co-medication next to MMF, all patients were divided into three groups 
(cyclosporine, tacrolimus, no calcineurin inhibitors). These non significant differences 
are shown in Figure 2 (p=0.247). A similar plot could be derived from difference in 
apparent clearance (data not shown). Based on the comparable dose-adjusted AUCs of 
patients on tacrolimus or cyclosporine in contrast to group 1 (no calcineurin inhibitors), 
this led towards further analysis based on two groups, one group with calcineurin 
inhibitors (cyclosporine or tacrolimus) and one group without calcineurin inhibitors. This 
classification, based on clinical selection, was used for further development of limited 




















Figure 2: Patients without calcineurin inhibitors; patients with cyclosporine and patients with 
tacrolimus as co-medication next to MMF and their (non significant) difference in dose adjusted AUC 
(p=0.247). The circles in the plot indicate individual (cyclosporine) patients outside the range. 
Development of limited sampling models 
Different groups of models based on renal function and co-medication were developed 
in MW\Pharm. For four patients the model building procedure in MW\Pharm could not 
describe the data adequately according to the population model including the total 
patient population. Six patients with deviant albumin levels (outside reference range  
of 40-50 g/L) were excluded when developing the model because MPA concentration 
levels are positively associated with serum albumin levels23. When developing  
PK models these patients (n=10) were excluded for model building on the condition 
that the final model should improve the prediction of the apparent clearance for these 
individuals compared to the base model including their data. The PK models were 
developed based on the remaining 24 patients.  
Population parameters for the CNI as well as the no-CNI group were calculated. 
Because of nephrotoxicity of CNIs also POP-PK models were developed for groups based 
on creatinine clearance instead of co-medication. The POP-PK parameters for MMF 
limited sampling models both for patients with and without CNI co-medication are 
shown in Table 2. The apparent oral clearance (CL/F) is on average more than 50% 
higher for the group with CNIs compared to the group without CNIs. 
 
Parameters CNI (n=16) Without CNI 
(n=8) 
 population ± population ± 
Apparent clearance (L/h/70kg) 17.66 7.15 11.19 4.43 
Volume (central) (L/kg) 0.2585 0.2546 0.1476 0.1589 
Intercompartimental clearance 
(L/h/70kg) 
22.82 16.37 35.69 10.14 
Volume (peripheral) (L/kg) 3.0042 3.4748 2.2672 2.1192 
Absorption rate constant (/h) 7.0165 12.2131 33.13 65.03 
Oral bioavailability 1 fixed 1 fixed 
Lagtime (h) 0.3366 0.1966 0.4893 0.0100 
Table 2: Population pharmacokinetic parameters for CNI-group (16 patients) and group without CNI (8 
patients) 
 
Based on the individualized PK parameters for both groups with and without CNI,  
AUCs of different limited sampling models based on one- or multiple point sampling 
were calculated. Correlations of these calculated AUCs with trapezoidal AUC0-12h 
including bias and precision for both groups are shown in Table 3.  
 
Blood sampling time points CNI (n=16) Without CNI (n=8) 
  r² MPE MAPE r² MPE MAPE 
0 0.89 6 20 0.68 16 20 
0-0.5-3 0.87 15 27 0.51 30 31 
0-0.5-1-2 0.82 14 24 0.85 14 20 
0-1-2-3 0.75 12 29 0.78 19 21 
0-0.5-1-2-3 0.69 35 45 0.80 18 19 
0-3-4-6 0.93 15 26 0.44 32 34 
3-6 0.59 15 29 0.72 4 17 
0-0.5-1-2-3-4-6 0.91 6 14 0.86 11 13 
Table 3: Correlations of MPA-AUC calculated for models with and without CNI with trapezoidal  
AUC0-12h (n=24, CNI: n=16, without CNI: n=8) 
 
These time points are a selection of the best of 30 investigated combinations of blood 
sampling time points. Especially the combination 0-½-1-2h shows very good 
correlations with trapezoidal AUC0-12h for both models (with and without CNI), with 
acceptable bias and precision (CNI: r²=0.82, MPE/MAPE 14/24; without CNI:  
r²=0.85, MPE/MAPE 14/20). 
The correlations, bias and precision of the groups based on creatinine clearance were 
inferior to the groups with and without CNI (data not presented). 
Correlation of MPA-trough-levels with trapezoidal AUC0-12h for all patients (n=34) 
without using any limited sampling model was surprisingly good, r²=0.81 (p<0.05). 
This relationship for the different types of co-medication (without CNI, cyclosporine, 
tacrolimus) is shown in Figure 3, which underlines our division of co-medication in 
groups with and without CNI. The correlation of trough level (C0) with trapezoidal 
AUC0-12h, with the use of limited sampling models, was reasonable (r²=0.89) in 
patients on CNI (n=16) versus a lower correlation (r²=0.68) for patients without CNI 
























Figure 3: Relationship of MPA trough level with trapezoidal AUC0-12h for different groups of  





We could adequately describe the pharmacokinetic profile of MPA in liver transplant 
patients. There appeared to be a linear relationship between MMF dose and the area 
under the concentration time curve (AUC) with the remark that a 7-fold variability in 
MPA apparent clearance was observed. Part of this variability could be associated with 
the covariates serum albumin concentration and creatinine clearance (CRCL). This 
analysis was the basis for a proposal to improve TDM in liver transplant patients: we 
developed limited sampling models for MPA TDM for different groups of patients and 
depending on co-medication (with and without CNI) or renal function.  
Some combinations of time points showed excellent correlation with trapezoidal  
AUC0-12h, for patients on CNI even with trough level monitoring, when using a limited 
sampling model. However, with the model of patients without CNI therapy only a 
moderate correlation of MPA trough level with trapezoidal AUC0-12h was found. Since 
our Bayesian models have no need for fixed time points they are very flexible and easy 
to use in daily practice in the outpatient clinic, as we have shown before for 
























MPA without CNI MPA + CsA MPA + TRL
The trough level without the model demonstrated a nice correlation with trapezoidal 
AUC, however our dataset is too small to show the imprecision for this method. One 
could note the possible imprecision for the trough level approach, as is known for the 
CNI‟s from Figure 3 (middle plot). A 4-fold difference is observed between trough level 
and AUC despite the good correlation between trough level and AUC. This large 
difference in AUC at a measured trough level (i.e. 0.5 mcg/L) is a reflection of the large 
interpatient variability and is a pitfall in trough level approach. However, for MMF  
a larger cohort should support these findings. 
There are several reasons for introducing therapeutic drug monitoring of 
mycophenolate mofetil in daily practice. MPA levels are related to efficacy (rejection) 
and safety (adverse events)3-6. A recent article from Yau et al. already concluded that 
fixed dose regimens of MMF may not be optimal for all patients25. Another important 
reason is the inter-patient variation in MPA pharmacokinetics, due to factors such as 
renal function, albumin level and (cyclosporine) co-medication23,26-29. One third of 
patients on cyclosporine receiving fixed dose MMF immediately after renal 
transplantation were underdosed when the AUC was calculated, and this was related to 
a higher incidence of rejection30. Furthermore, an increase of Cmax and AUC of MPA in 
renal transplant recipients in the months after transplantation is described31. This may 
require dose adjustments.  
Calcineurin inhibitors are widely used after organ transplantation. A disadvantage of 
these drugs is their nephrotoxicity. MMF, in contrast to CNIs, does not cause renal 
damage. Its use may lead to lowering or even discontinuation of CNI-dosing32,33. The 
discontinuation of CNI may lead to better kidney function in the long term9,34. However, 
conversion to fixed dose MMF monotherapy (or with steroids) after liver transplantation 
may lead to acute or even chronic rejection in a significant percentage of the  
patients8-11. A solid TDM-based dose guiding strategy for MPA may reduce these risks. 
In addition, with this approach we can get a clear understanding of the relationship with 
MPA toxicity in a CNI free regimen in the context of higher MMF doses. 
A recent review article from Kaplan concluded that the contribution of TDM for MMF in 
the investigated studies remains unproven and that results of large randomized 
controlled trials are awaited14. Another review article from Arns et al. concluded that 
there still was no clear support for a substantial clinical benefit of TDM, but that MPA 
area under the curve might be more reliable than predose (C0) MPA levels13. Zicheng et 
al. developed rigid limited sampling algorithms for implementation of MPA-monitoring in 
liver transplantation necessitating exactly timed blood sampling20. In the roundtable 
meeting of Van Gelder et al. also different limited sampling strategies, mostly 
algorithms, for monitoring MPA were described as good estimators of AUC0-12h with 
acceptable predictive performance35. Based on the MPA AUCs in our patients on 
tacrolimus, cyclosporine or without CNI it appeared necessary to divide the liver 
transplant patients in one group with calcineurin inhibitors (no difference between 
tacrolimus or cyclosporine) and another group without calcineurin inhibitors and to 
develop two separate LSMs for these two groups. 
The program used for Bayesian estimations is a two stage approach which is able to 
predict PK parameters adequately in strictly defined populations. The studied population 
of liver transplant patients displays large inter-individual variability with a 7-fold 
apparent clearance difference. Therefore we had to make a patient selection  
(i.e. albumin selection) which at first sight seems to indicate bias and would not reflect 
the clinical situation. However, with this selection we were able to build a model with 
more degrees of freedom which has the advantage to estimate individual (post hoc) PK 
parameters more accurately and precise. This is reflected and justified by the fact that 
these excluded patients - both groups of 4 patients who did not adequately described 
the data during model building and the 6 patients with deviant albumin levels - fitted 
better in the newly developed model. However, this does indicate that the model should 
be validated on a larger dataset before introduction in clinical practice. 
One should note that the CNI free group demonstrated low CRCL, which is an artefact 
caused by rather late conversion of patients with deteriorated kidney function to a  
CNI free regimen. Also, the correlations, MPE and MAPE of the groups based on 
creatinine clearance were inferior to the groups with and without CNI. When the trend 
evolves to minimize or discontinue CNIs, our MPA classification provides an excellent 
tool for continuation of therapeutic drug monitoring of MMF. 
The distinction between cyclosporine/no-cyclosporine as co-medication of MMF is 
described in different studies26,36-39. Cyclosporine has an influence on MPA clearance by 
disrupting the enterohepatic cycle, leading to lower MPA exposure40. However, we did 
not find a difference in MPA AUCs between patients on tacrolimus and those on 
cyclosporine. A limitation of our study is the absence of blood sampling time points 
between 6 and 12 hours after dosing MMF, exactly the time in which the enterohepatic 
recirculation may occur. Due to these missing values we could not take the 
enterohepatic cycle into account, which may mean that the MPA AUCs in patients using 
cyclosporine may be slightly higher than calculated in our study. However, the absence 
of a difference in trough levels between the CNI groups (same dose range) indicates 
that this effect might not be relevant for MPA in liver transplant patients. Because of 
possible disturbances in bile production and flow the influence of the enterohepatic 
cycle might be different in liver transplant patients compared to renal transplant 
recipients41. Figure 3 suggests that both CNIs may cause a higher CL/F of MPA and 
therewith a lower MPA exposure than in patients without CNI. However, as earlier 
mentioned, this could also be biased by kidney function or by albumin concentration.  
Because the models we developed are based on a limited number of patients, we are 
planning to validate these models.  
In addition, we will implement limited sampling models with more time points than may 
be needed to achieve more information during this prospective validation. Also the role 
of trough level-monitoring in combination with a POP-PK model, which appeared to be 
reliable in patients on CNI according to our findings, and the clinical relevance, need 
further validation on a larger dataset. The LSM seems excellent with sampling at  
0-½-1-2h for both groups with and without CNIs, with good correlations with 
trapezoidal AUC0-12h and acceptable bias and precision. 
No target ranges for the MPA AUC especially for liver transplantation patients have been 
developed yet. In the scarce literature about TDM of MPA after liver transplantation 
Tredger et al. suggests a therapeutic range of 1 to 3.5 mg/L for trough-level monitoring 
in order to prevent acute rejection and to lower adverse effects, like infection, 
leucopenia and gastrointestinal disturbances19. For renal transplantation in the early 
post-transplant period, an AUC0-12h range of 30-60 mg.h/L is adhered to in the 
presence of a CNI35. De Fijter et al. suggests that a target AUC of 75 mg.h/L  
(range 60-90 mg.h/L) for kidney transplant recipients allows cyclosporine withdrawal, 
and with this target range very few patients developed acute rejection42. For the 
moment we suggest - in the absence of sufficient data from clinical studies - to use 
similar targets in liver transplantation as in renal transplantation42. Especially for the 
patients without CNI with increased risk of (chronic) rejection, the lower side of the 
AUC range (60 mg.h/L) seems to be more important than the danger of (reversible) 
toxicity from high levels, which is easier to recognize and usually rapidly responds to 
dose lowering.  
In conclusion, with our two flexible and accurate Bayesian limited sampling models for 
MMF (e.g. with sampling times 0-½-1-2h) based on co-medication with or without 
calcineurin inhibitors we developed a tool for improving therapeutic drug monitoring 
based dose guiding of MMF in liver transplant patients. This becomes especially 
important when one wants to avoid rejection while lowering or discontinuing calcineurin 
inhibitors in order to improve renal function. Prospective validation and assessment of 
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After using C0-monitoring as the tool for therapeutic drug monitoring of cyclosporine 
for many years, studies suggested that C2-monitoring might be better in terms of 
predicting systemic exposure to cyclosporine. After switching 31 liver transplant 
patients using cyclosporine from C0 to C2 monitoring in chapter 2 in 21/31 patients 
(68%) the cyclosporine dose was lowered and in the other patients the dose remained 
unchanged. For patients whose dose of cyclosporine was lowered,  improvement of 
renal function and some decrease in mean- and systolic morning blood pressure was 
observed. C2 correlated better (r² = 0.75) than C0 (r² = 0.64) with the area under the 
curve after the first 12 hours after dosing (AUC0-12h). A problem we observed was the 
significant intrapatient variability. In 13/21 patients whose dose was lowered the 
second AUC was below the target range but only 2/13 developed rejection.  
Because of the problem of overdosing with C0-monitoring and episodes of underdosing 
with C2 monitoring in chapter 3 we developed new, accurate and flexible limited 
sampling strategies to optimize therapeutic drug monitoring of cyclosporine. We 
developed (rigid) limited sampling formulas (LSF) and flexible limited sampling models 
(LSM). The models showed even better correlations with AUC0-12h than the formulas. 
Combinations of blood sampling time points 0+2h (r² = 0.94); 0+1+2h (r² = 0.94); 
0+1+3h (r² = 0.92); 0+2+3h (r² = 0.92) and 0+1+2+3h (r² = 0.96) showed excellent 
correlation with AUC0-12h with acceptable precision and bias.  
When evaluating in chapter 4 the LSM 0+1+2+3h model that best correlated with 
AUC0-12h in the 18 months after introduction there was no significant change in 
average cyclosporine dose and creatinine clearance, compared to the previous  
C2-monitoring. Also the number of rejections was comparable. There was wide inter- 
and intrapatient variability in the time to reach peak concentrations of cyclosporine 
after dosing. The variation coefficient of clearance based on all patients was 15%. When 
investigating the required precision, the correlation of two 2-point and three 3-point 
models with LSM 0+1+2+3h were very good with acceptable bias and precision:  
LSM 0+2h (r² = 0.88); LSM 0+3h (r² = 0.87); LSM 0+1+2h (r² = 0.84); LSM 0+1+3h  
(r² = 0.91) and LSM 0+2+3h (r² = 0.92). We also calculated these correlations per 
patient and these results show that other limited sampling models with less time points 
show comparable results as LSM 0+1+2+3h. Especially LSM 0+2h was optimal in terms 
of accuracy, ease-of-use and intrapatient variability.  
When optimizing tacrolimus monitoring after calculating limited sampling formulas 
(LSF) in chapter 5 different single point and multiple-point combinations showed good 
correlations with AUC0-12h: LSF 4h (r² = 0.94); LSF 6h (r² = 0.90); LSF 8h  
(r² = 0.93); LSF 1+4h (r² = 0.96); LSF 0+2+3h (r² = 0.95) and LSF 0+1+3h  
(r² = 0.98). The best single point calculation in terms of estimating systemic tacrolimus 
exposure using limited sampling models (LSM) were LSM 4h (r² = 0.97) and LSM 6h  
(r² = 0.97). Also, multiple-point LSMs showed excellent correlation with AUC0-12h. The 
correlation of the widely used C0 with AUC0-12h was not as good for both LSF and LSM 
(r² = 0.68 and 0.87), both also with relatively high prediction precision errors  
(MAPE 17% and 14%). The new calculated AUC target range for tacrolimus was 95-190 
h.µg/L. 
 
During the study of the pharmacokinetic behaviour of MMF in chapter 6 we found a 
linear relationship between MMF dose and trapezoidal MPA area under the curve. There 
was a wide range in MPA clearance in the population (8.08 – 57.47 L/h). Looking at 
possible sources of this variability in MPA clearance, there appeared to be a significant 
inverse relationship between serum albumin concentration and MPA clearance  
(r² = 0.26, p<0.05). There also was a significant relationship between creatinine 
clearance and MPA clearance (r² = 0.36, p<0.05). 
Based on clinical selection, two groups (with and without calcineurin inhibitors) were 
used for further development of limited sampling models for therapeutic drug 
monitoring of MPA.  
Based on the individualized PK parameters for both groups with and without CNI, AUCs 
of different limited sampling models based on one- or multiple point sampling were 
calculated. The combination 0-½-1-2h showed very good correlations with trapezoidal 
AUC0-12h for both models (with and without CNI), with acceptable bias and precision 
(CNI: r²=0.82, MPE/MAPE 14/24; without CNI: r²=0.85, MPE/MAPE 14/20). 
Correlation of MPA-trough-levels with trapezoidal AUC0-12h for all patients (n=34) 
without using any limited sampling model was surprisingly good, r²=0.81 (p<0.05). 
The correlation of trough level (C0) with trapezoidal AUC0-12h, with the use of limited 
sampling models, was reasonable (r²=0.89) in patients on CNI (n=16) versus a lower 






Switching cyclosporine monitoring from C0- via C2-monitoring and subsequently to LSM 
0+1+2+3h allowed us to compare the biochemical and clinical effects of these three 
methods. 
During the conversion from C0 to C2 cyclosporine monitoring in stable patients more 
than 6 months after liver transplantation, we saw a significant decrease in cyclosporine 
dose in two-thirds and an unchanged dose in one-third of the patients. Dose reduction 
resulted in lower systemic exposure and an improvement of renal function, but only 
small but significant changes in morning systolic and mean morning blood pressures 
were observed, with questionable clinical significance. The fact that the kidney function 
did not improve in all patients who had a dose reduction may be due to long-term 
exposure to cyclosporine, which may have caused a fixed renal insufficiency. Also, 
further improvement in renal function might require more time. Based on calculating 
the area under the concentration time curve from 0 to 12 hours (cyclosporine blood 
levels), the correlation of C2 with AUC0-12h was better than the correlation of C0 with 
AUC0-12h.  
However, in almost one-half of the patients, there was significant intrapatient variability 
of the C2 blood levels with the same dose. This made therapeutic drug monitoring with 
C2 levels less accurate and may induce many unnecessary subsequent changes in drug 
dose, which is inconvenient for patients, doctors and nurses. We found it disturbing 
that, although two preceding C2 levels were within the 600 ng/mL ± 15% range, in 
13/21 patients whose dose was lowered the second AUC was below the target AUC of 
3380 – 4266 h.µg/L, although only 2 out of these 13 patients developed rejection. The 
fact that these patients were 9 and 10 months post OLT may mean that the dose 
recommendations of G. Levy and not those of E. Cole should be followed when using  
C2 monitoring1,2. 
While on C2 monitoring, 17/31 patients had a second AUC outside the AUC target 
range. Not all patients  may need to have an AUC within the range of the „target range 
AUC‟. It seems safer if the value is within the target range, but this may lead to an 
unnecessary worse renal function. A compromise would be to have an AUC on day 2 in 
the lower half of AUCs while on C0, which is 3380 – 3823 h.µg/L. Because  
11/13 patients with an AUC below the target AUC while on C2 monitoring did not 
develop rejection, many patients may tolerate lower AUCs.  
Other studies saw a better correlation of C2 with AUC when compared to trough-level 
monitoring in renal and liver transplant recipients3-15. Most studies in renal 
transplantation and the limited studies in liver transplantation using C2 monitoring also 
showed improved kidney function. Often blood pressure and serum cholesterol also 
improved. In those studies no rejection occurred despite lower exposure to 
cyclosporine. However, in the liver transplant studies mentioned AUC was calculated by 
measuring multiple cyclosporine blood levels during 4 and 6 hours post-dosing only, 
while we used 0-12 hour AUCs. This fact may explain some of the difference between 
these and our studies. Another explanation for the difference with the kidney studies 
may be the lower maintenance levels used in liver transplantation when compared to 
kidney transplantation: further lowering of the already low dose after liver 
transplantation may more easily lead to rejection.  
In our study all cyclosporine concentration blood samples were taken as  
recommended 1,2,16 and within 2 minutes from the targeted time (although 10 minutes 
are allowed); if sampling time would have been more variable (as may be the case in 
daily practice), an even lower accuracy of C2 monitoring and inappropriate dose 
adjustments might occur17. In renal transplantation variable cyclosporine levels may 
contribute to chronic rejection18. Although chronic ductopenic rejection has become less 
common after liver transplantation in the past decade, it forms a continuum with acute 
cellular rejection; chronic underexposure to cyclosporine can be a cause19-22. In renal 
transplant studies it was shown that absorption profiling over the first 4 hours was 
superior to trough-level monitoring, with C2 as the best single-point predictor of 
AUC3,23-26. The clinical superiority of such absorption profiling over C2 levels has not 
been examined in those studies. Our data demonstrated that in stable liver transplant 
patients trough-level monitoring frequently leads to overdosing of cyclosporine, while 
monitoring by C2 may cause episodes of underdosing in some patients. Therefore, 
better ways of monitoring cyclosporine dosing in liver transplantation were awaited.  
Because both IL2 blood concentration and AUC0-12h are related to cyclosporine 
exposure in the first 4 hours after dosing it seems logical to use a sparse-sampling 
method over the first hours after dosing. In accordance with others, our data 
demonstrated that, if AUC is calculated from cyclosporine levels, using the trapezoidal 
rule, in the first 3 hours after dosing the correlation with AUC0-12h is 0.96
23,27. Thus use 
of a sparse sampling method may avoid over- and underdosing and unnecessary 
changes in dose.  
We then developed a new, accurate, flexible and precise method for cyclosporine 
monitoring in stable patients more than 6 months after liver transplantation based on 
an individualized population pharmacokinetic (PK) limited sampling model. This 
contrasted to most limited sampling strategies in that the other strategies were only 
based on population pharmacokinetics, while our PK model is based on population 
pharmacokinetics as well as Bayesian fitting of limited sampling data from one patient. 
A major advantage of the new method over methods based on population kinetics only 
was that sampling time points are more flexible than with C2 monitoring, limited 
sampling formulas (LSFs) or current POP-PK models. Our model is efficient as long as 
the exact dosing and sampling time, the weight of the patient and the dosing rhythm 
are registered and sampling time is near the required time after dosing. Both 
population and individual kinetics are incorporated in the model, making optimal use of 
all available information. Blood concentration data are put into the computer model, 
which runs on a desktop PC, the AUC is calculated and a dose modification is 
suggested. It is still necessary to obtain more than one blood concentration of 
cyclosporine during the dosing interval in order to obtain adequate estimates (>90%) 
of AUC0-12h.  
For cyclosporine the correlation with AUC0-12h of the individualized POP-PK model was 
better than with LSFs, especially when less than three sampling points were used. The 
models with sampling time points 0+2h; 0+1+2h; 0+1+3h; 0+2+3h and 0+1+2+3h 
showed excellent correlation (r² > 0.90) with the gold standard AUC0-12h. Results 
even for C0 combined with the model were better than those for simple C0 or C2. The 
r² for C2 was below 0.80 even with an individualized POP-PK model or LSF. It was 
almost always necessary to include a trough blood sample in the LSMs in order to 
achieve  a correlation (r²) > 0.90.  
Based on the developed POP-PK model and generally accepted cyclosporine trough 
levels of 90–125 µg/L, the AUC range should be 2900–3800 h.µg/L. We introduced this 
target range into our clinic, although from the previous studies we knew that some 
patients may tolerate lower values.  
Using an individualized POP-PK model with multiple sampling points requires some 
organization in the clinic but in our experience this is feasible and the advantages are 
clear.  
It had already been shown that using multiple sampling points in the first hours after 
dosing with Bayesian forecasting results in a better correlation with AUC0-12h28–31. A 
high inter-individual variability in cyclosporine pharmacokinetics exists, which seems 
unrelated to CYP3A polymorphisms32. Therefore, the use of multiple sampling models 
may avoid over- and underdosing and unnecessary changes in dose. A disadvantage of 
available LSFs and POP-PK models was that multiple samplings were needed on fixed 
time points. It was previously stated that the ideal model should be easy to use and 
flexible, without the rigid time points and complicated methods used in current multiple 
sampling models. Ideally it should be based both on population kinetics and on 
individual pharmacokinetics30,31,33,34. The LSM 0+1+2+3h we presented clearly 
approximated this goal. A similar model performed well in kidney as well as combined 
kidney–pancreas transplant patients35. Because of the superiority of LSM 0+1+2+3h  
(r² = 0.96) we introduced this model into our clinic. 
Next, in stable patients it might in the long term be possible to reduce both the number 
of samplings per visit and the number of visits to the clinic while still getting sufficient 
prediction of AUC. We therefore evaluated our model after using it for more than  
18 months. We showed that our LSM 0+1+2+3h-method accurately estimated systemic 
exposure to cyclosporine in OLT patients. However, there appeared to be considerable 
intra-patient variability in the time to reach the peak-concentration of cyclosporine. This 
led to the same number of dose adjustments as with C2-monitoring in the 18 months 
before the switch from C2 to LSM 0+1+2+3h. The intrapatient pharmacokinetic 
variability may partially be due to interaction with food or other medication. The 
variation in peak-time is partially responsible for the large intra-patient variation in  
C2 levels over time in some of the patients. Using a limited sampling model with more 
sampling time points all important information required for calculating an AUC is 
obtained and the chance of ´missing´ this variability is less, which leads to more 
accurate AUC estimations. 
After more than 1,5 year of using our model for cyclosporine monitoring in the 
outpatient clinic 152 LSM 0+1+2+3h curves from 30 patients were derived. Although 
this was not a randomized controlled trial these stable patients were their own controls. 
According to the dose, renal function and rejection on average there was no difference 
using C2-monitoring or the individualized PK-model. However, the target range was 
based on AUCs while on C0-monitoring. In the first study, while on C2-monitoring, we 
saw two rejections in 13 cases where the AUC dropped below the AUC target-range. 
Apparently an AUC below 2900 h.μg/L was tolerated in most of these patients. This was 
similar for LSM 0+1+2+3h monitoring: for some patients the dose was not increased 
because of renal insufficiency if LSM 0+1+2+3h gave an AUC below the target range , 
but in spite of that usually no signs of rejection occurred. 
Although there was no significant change in creatinine clearance between  
C2-monitoring and LSM 0+1+2+3h there seemed to be a trend toward lower CRCL with 
LSM versus C2-monitoring (p=0.071), despite the fact that the same target range for 
AUC was used. More data is needed to confirm that cyclosporine dosing by LSM may 
lead to less toxicity than C2-based dosing. 
The current data allowed us to investigate the true natural variability in PK of 
cyclosporine in stable OLT-patients. The mean intra-patient variability of the apparent 
oral clearance of cyclosporine in these stable liver transplantation patients was 15%. 
This means that a dose-adjustment of 16 mg or less (15% of mean dose of 109 mg) is 
not rational, because this difference is a natural variation which cannot be avoided. In 
fact, the lowest possible dose adjustment (25 mg) in practice is relatively close to this 
natural variation of 16 mg. In case the mean dose of 109 mg and a 95% confidence 
interval (mean ± 2.SD) would be used, a target range of 2380-4390 h.µg/L would be 
rational. In other words, any AUC-value within this range can be explained by natural 
variability in PK of cyclosporine and may therefore not require a dose adjustment. In 
our hospital a target-range of 2900-3800 h.μg/L was used for stable OLT patients, 
which is narrower, and closer to a mean ± 1.SD value of the AUC in this population, 
which is 2680-3620 h.μg/L. However, to be on the safe side until now we remain 
adhering to this narrow range, although we realize that this may be too strict. Based on 
the current data, a lower range for the AUC than currently used with a target AUC of 
2830 h.μg/L (2380-3280 h.µg/L) may be reasonable. Our data suggest that, 
considering the natural variability in PK of cyclosporine in stable OLT patients, our 
method with LSM 0+1+2+3h may be unnecessary accurate in terms of estimating 
systemic exposure to cyclosporine.  
When investigating the correlation between LSMs with only two or three sampling 
points and LSM 0+1+2+3h we see that overall five models showed good correlation 
when considering both the AUCs and the mean advised dose. These five LSMs were 
0+2h; 0+3h; 0+1+2h; 0+1+3h and 0+2+3h. Accuracy and bias were acceptable. The 
trough level is included into all of these models, which (again) illustrates the pivotal 
role of this trough sample for assessing systemic exposure to cyclosporine, although 
models on C0 only are inaccurate. When developing the model we already noticed a 
very good correlation of these models with the gold standard AUC0-12h (for LSM 0+2h 
this was: r²=0.94, MPE=-9, MAPE=9) with less bias and greater precision than e.g. C2 
single-point monitoring (r²=0.78, MPE=-10, MAPE=12) or Ctrough36. In spite of the fact 
that LSM 0+1+2h includes both the common 1- and 2-hour peak-level time points, the 
correlation of this model with LSM 0+1+2+3h in the patients with five or more curves is 
not different from LSM 0+2h (r²= 0.84-1.00 vs 0.81-0.99). Comparing LSM 0+1+2h 
with LSM 0+2h, the 0+2h-model has the benefit that it is easier to apply in practice, it 
is more friendly for the patient and the medical staff, and there is a cost-benefit. 
Therefore this model seems to be an optimal balance between patient benefit and 
discomfort. A large randomized controlled trial between C2 and LSM 0,2h with a target 
AUC of 2830 h.µg/L (range 2380-3280 h.µg/L) would be of interest. 
In conclusion, while cyclosporine C0-monitoring frequently results in overdosing and 
more renal dysfunction, C2-monitoring may lead to episodes of underdosing but 
rejection in only some of these patients and it may lead to many subsequent dose 
adjustments. We therefore devised and introduced a flexible Bayesian individualized 
population pharmacokinetic limited sampling model for cyclosporine monitoring, without 
rigid sampling time points. This model is accurate and easy to use in daily practice. 
After using LSM 0+1+2+3h for more than 18 months we showed the feasibility of 
implementation of this method. Considering the natural variability in pharmacokinetics 
of cyclosporine LSM 0+1+2+3h may be unnecessary accurate in terms of estimating 
systemic exposure of cyclosporine. Reducing the numbers of samplings per visit to  





Therapeutic drug monitoring of tacrolimus in many clinics is based on trough-level  
(C0) monitoring. Recent studies including patients with varying time after 
transplantation and different types of organ transplantation showed that C0 might be 
not the best estimator of systemic exposure of tacrolimus37-39. 
In our study we demonstrated that indeed C0 monitoring is not very precise for 
tacrolimus monitoring after OLT and that this time point does suboptimally reflect 
systemic exposure to tacrolimus in the first 12 hours after dosing. We investigated 
strategies for tacrolimus monitoring and developed and validated individualized 
population pharmacokinetic (POP-PK) models based on blood sampling time points  
C4 or C6, which appeared to very accurately reflect systemic exposure of tacrolimus 
with excellent precision. Our finding that sampling between 4 and 6 hours after dosing 
seems optimal was in line with two other studies that suggest C4 and C5 sampling 
respectively40,41. Others also found C0 to be not very accurate in different patient 
populations42,43.  
In our study the results concerning correlation with AUC0-12h for both calculated 
limited sampling formulas (LSF) and LSM were satisfying, with slightly better results for 
the model. The advantage of the formula is the simplicity of the calculation. The 
advantage of the model above LSF is that the model is flexible and no fixed time points 
are needed, in contrast to the rigid formulas.  
Comparing single- and multiple-point monitoring the latter group showed in most cases 
an almost perfect correlation with AUC0-12h. But, in spite of this slightly better 
correlation, LSM C4h and LSM C6h already had r²‟s of 0.97. Therefore, single-point 
LSMs seem sufficient. For practical reasons both the C4 and the C6 model seem 
feasible. Patients can take their medication at home at the normal time, visit the 
hospital for checkup and blood is taken 4-6 hours after taken the morning dose. In 
contrast to C0 monitoring this new method does not interrupt the regular dosing, 
improving compliance and reducing error in measuring levels. Because the model is 
based on Bayesian estimation, there is no need to take the blood sample exactly on 
time, as long as the dosing and blood sampling time are recorded. The measured blood 
concentration is introduced in the model and after estimating the individual clearance 
the AUC is calculated and a dose advice is given. These factors in combination with the 
adequate performance of the model in the outpatient setting, which is normally a 
source of variability, provides with a tool for improved monitoring of tacrolimus. 
A limitation of our models and formulas is that these were developed and validated in 
two small independent groups of stable patients more than 6 months after OLT  
(11 and 12 patients). Given the considerable changes in tacrolimus kinetics shortly 
after transplantation, we do not recommend using these models in less stable patients 
early post transplant. For these patients new models need to be developed and 
validated.  
The calculated AUC target range based on C0 monitoring (90 - 195 h.µg/L) is very 
wide, which also suggests that C0 monitoring is not the optimal way for therapeutic 
drug monitoring of tacrolimus. In kidney transplantation in our clinic for stable patients 
a target AUC of 125 h.µg/L is adhered to (range 100 - 150 h.µg/L), corresponding to a 
target trough-level of 7.5 µg/L43. Currently, in the field of OLT a trend towards 
reduction in (nephrotoxic) calcineurin inhibition is noticeable. Moreover, in a review 
article from Staatz et al. also lower targets are described for liver transplantation 
compared to kidney transplantation44. With respect to this trend and after observing 
Figure 1 depicting our data we decided to adopt a new target range, which is slightly 
lower than used for stable kidney transplantation patients  more than 6 weeks after 
transplantation, and also lower than the range corresponding with C0 = 5 - 10 µg/L 

















Figure 1: Relationship between trough level (C0) and AUC of all 23 patients, while on C0-monitoring. 
The thin dotted lines (……) show the range based on trough-level monitoring of 5-10 µg/l  
(AUC target 142.5 h*µg/l). The other lines ( - - - - - ) show the proposed AUC range based on  
trough-level monitoring of 4-8 µg/l which is 80% lower than 5-10 µg/l (AUC target 110 h*µg/l,  





We lowered the C0-range from 5 - 10 µg/L to the (arbitrary) range of 4 - 8 µg/L, which 
is 80% of the original range. When calculating a new AUC target and AUC target range 
we calculated 80% of the original AUC target (142.5 h.µg/L) and based the target 
range on the lowest possible dose-adjustment of 0.5 mg, which would be respectively 
110 h.µg/L for the target and 90 - 130 h.µg/L for the range. The new target AUC of  
110 h.µg/L is based on the C0-level of (4 + 8) / 2 = 6 µg/L. The new range  
(90 - 130 h.µg/L) is wider than the lowest possible change due to a dose adjustment of 
0.5 mg, which makes it practical in daily use. The new target is visualized in Figure 1 
and the clinical consequences of C4 monitoring with this range are currently being 
studied prospectively. 
 
High tacrolimus exposure should be avoided in the stable phase post OLT since clinically 
relevant toxicity, such as nephrotoxicity, can have a clearly negative impact on patient 
and graft survival45,46. The current trend towards lower target ranges underlines the 
need for precise monitoring, since tacrolimus underexposure and rejection should be 
avoided. 
In conclusion, in our study C0-monitoring of tacrolimus (Prograft BID) did not have a 
good correlation with AUC0-12h using LSF (r² = 0.68) or without using LSF and LSM  
(r² = 0.69). Correlation of C0 with AUC0-12h using LSM seems to be acceptable  
(r² = 0.87) but concentrating on MPE and MAPE we have to conclude that prediction 
precision errors (MAPE) are not in our range of ±10% (MAPE 14%). This confirms that 
trough-levels do not very well reflect systemic exposure of tacrolimus. Limited sampling 
models and limited sampling formulas based on sampling time points 4h or 6h showed 
excellent correlation with AUC0-12h, with acceptable bias and precision. We are 
currently further validating C4 monitoring in a randomized controlled trial. 
Mycophenolate mofetil 
We could adequately describe the pharmacokinetic profile of MPA in liver transplant 
patients. There appeared to be a linear relationship between MMF dose and the area 
under the concentration time curve (AUC) with the remark that a 7-fold variability in 
MPA apparent clearance was observed. Part of this variability could be associated with 
the covariates serum albumin concentration and creatinine clearance (CRCL). This 
analysis was the basis for a proposal to improve TDM in liver transplant patients: we 
developed limited sampling models for MPA TDM for different groups of patients and 
depending on co-medication (with and without CNI) or indirectly renal function. 
Some combinations of time points showed excellent correlation with trapezoidal  
AUC0-12h, for patients on CNI even with trough level monitoring, when using a limited 
sampling model. However, with the model of patients without CNI therapy only a 
moderate correlation of MPA trough level with trapezoidal AUC0-12h was found. Since 
our Bayesian models have no need for fixed time points they are very flexible and easy 
to use in daily practice in the outpatient clinic, as we have shown before for 
cyclosporine monitoring47. The trough level without the model demonstrated a nice 
correlation with trapezoidal AUC, however our dataset is too small to show the 
imprecision for this method. One could note the possible imprecision for the trough 
level approach, as is known for the CNI‟s from Figure 2 (middle plot). A 4-fold 
difference is observed between trough level and AUC despite the good correlation 
between trough level and AUC. This large difference in AUC at a measured trough level 
(i.e. 0.5 mcg/L) is a reflection of the large interpatient variability and is a pitfall in 
trough level approach. However, for MMF a larger cohort should support these findings. 
There are several reasons for introducing therapeutic drug monitoring of 
mycophenolate mofetil in daily practice. MPA levels are related to efficacy (rejection) 
and safety (adverse events) 48-51. An article from Yau et al. already concluded that fixed 
dose regimens of MMF may not be optimal for all patients52. Another important reason 
is the inter-patient variation in MPA pharmacokinetics, due to factors such as renal 
function, albumin level and (cyclosporine) co-medication53,54-57. One third of patients on 
cyclosporine receiving fixed dose MMF immediately after renal transplantation were 
underdosed when the AUC was calculated, and this was related to a higher incidence of 
rejection58. Furthermore, an increase of Cmax and AUC of MPA in renal transplant 
























Figure 2: Relationship of MPA trough level with trapezoidal AUC0-12h for different groups of  
co-medication next to MMF: without CNI, with cyclosporine (CsA) and with tacrolimus (TRL) 
 
 
Calcineurin inhibitors are widely used after organ transplantation. A disadvantage of 
these drugs is their nephrotoxicity. MMF, in contrast to CNIs, does not cause renal 
damage. Its use may lead to lowering or even discontinuation of CNI-dosing60,61. The 
discontinuation of CNI may lead to better kidney function in the long term62,63. 
However, conversion to fixed dose MMF monotherapy (or with steroids) after liver 
transplantation may lead to acute or even chronic rejection in a significant percentage 
of the patients62,64-66. A solid TDM-based dose guiding strategy for MPA may reduce 
these risks. In addition, with this approach we can get a clear understanding of the 
relationship with MPA toxicity in a CNI free regimen in the context of higher MMF doses. 
A review article from Kaplan concluded that the contribution of TDM for MMF in the 
investigated studies remains unproven and that results of large randomized controlled 
trials are awaited67. Another review article from Arns et al. concluded that there still 
was no clear support for a substantial clinical benefit of TDM, but that MPA area under 
the curve might be more reliable than predose (C0) MPA levels68. Zicheng et al. 
developed rigid limited sampling algorithms for implementation of MPA-monitoring in 
liver transplantation necessitating exactly timed blood sampling69. In the roundtable 
























MPA without CNI MPA + CsA MPA + TRL
algorithms, for monitoring MPA were described as good estimators of AUC0-12h with 
acceptable predictive performance70. 
Based on the MPA AUCs in our patients on tacrolimus, cyclosporine or without CNI it 
appeared necessary to divide the liver transplant patients in one group with calcineurin 
inhibitors (no difference between tacrolimus or cyclosporine) and another group without 
calcineurin inhibitors and to develop two separate LSMs for these two groups. 
The program used for Bayesian estimations is a two stage approach which is able to 
predict PK parameters adequately in strictly defined populations. The studied population 
of liver transplant patients displays large inter-individual variability with a 7-fold 
apparent clearance difference. Therefore we had to make a patient selection (i.e. 
albumin selection) which at first sight seems to indicate bias and would not reflect the 
clinical situation. However, with this selection we were able to build a model with more 
degrees of freedom which has the advantage to estimate individual (post hoc) PK 
parameters more accurately and precise. This is reflected and justified by the fact that 
these excluded patients, both groups of four patients who did not adequately described 
the data during model building and the six patients with deviant albumin levels, fitted 
better in the newly developed model. However, this does indicate that the model should 
be validated on a larger dataset before introduction in clinical practice. 
One should note that the CNI free group demonstrated low CRCL, which is an artefact 
caused by rather late conversion of patients with deteriorated kidney function to a CNI 
free regimen. Also, the correlations, MPE and MAPE of the groups based on creatinine 
clearance were inferior to the groups with and without CNI. When the trend evolves to 
minimize or discontinue CNIs, our MPA classification provides an excellent tool for 
continuation of therapeutic drug monitoring of MMF. 
The distinction between cyclosporine/no-cyclosporine as co-medication of MMF is 
described in different studies54,71-74. Cyclosporine has an influence on MPA clearance by 
disrupting the enterohepatic cycle, leading to lower MPA exposure75. However, we did 
not find a difference in MPA AUCs between patients on tacrolimus and those on 
cyclosporine. A limitation of our study is the absence of blood sampling time points 
between 6 and 12 hours after dosing MMF, exactly the time in which the enterohepatic 
recirculation may occur. Due to these missing values we could not take the 
enterohepatic cycle into account, which may mean that the MPA AUCs in patients using 
cyclosporine may be slightly higher than calculated in our study. However, the absence 
of a difference in trough levels between the CNI groups (same dose range) indicates 
that this effect might not be relevant for MPA in liver transplant patients. Because of 
possible disturbances in bile production and flow, the influence of the enterohepatic 
cycle might be different in liver transplant patients compared to renal transplant 
recipients76. Figure 2 suggests that both CNIs may cause a higher CL/F of MPA and 
therewith a lower MPA exposure than in patients without CNI. However, as earlier 
mentioned, this could also be biased by kidney function or by albumin concentration.  
Because the models we developed are based on a limited number of patients, we are 
planning to validate these models. In addition, we will implement limited sampling 
models with more time points than may be needed to achieve more information during 
this prospective validation. Also the role of trough level-monitoring in combination with 
a POP-PK model, which appeared to be reliable in patients on CNI according to our 
findings, and the clinical relevance, need further validation on a larger dataset. The LSM 
seems excellent with sampling at 0-½-1-2h for both groups with and without CNIs, with 
good correlations with trapezoidal AUC0-12h and acceptable bias and precision. 
No target ranges for the MPA AUC especially for liver transplantation patients have been 
developed yet. In the scarce literature about TDM of MPA after liver transplantation 
Tredger et al. suggests a therapeutic range of 1 to 3.5 mg/L for trough-level monitoring 
in order to prevent acute rejection and to lower adverse effects, like infection, 
leucopenia and gastrointestinal disturbances77. For renal transplantation in the early 
post-transplant period, an AUC0-12h range of 30-60 mg.h/L is adhered to in the 
presence of a CNI70. De Fijter et al. suggests that a target AUC of 75 mg.h/L  
(range 60-90 mg.h/L) for kidney transplant recipients allows cyclosporine withdrawal, 
and with this target range very few patients developed acute rejection78. For the 
moment we suggest - in the absence of sufficient data from clinical studies - to use 
similar targets in liver transplantation as in renal transplantation78. Especially for the 
patients without CNI with increased risk of (chronic) rejection, the lower side of the 
AUC range (60 mg.h/L) seems to be more important than the danger of (reversible) 
toxicity from high levels, which is easier to recognize and usually rapidly responds to 
dose lowering.  
In conclusion, with our two flexible and accurate Bayesian limited sampling models for 
MMF (e.g. with sampling times 0-½-1-2h) based on co-medication with or without 
calcineurin inhibitors we developed a tool for improving therapeutic drug monitoring 
based dose guiding of MMF in liver transplant patients. This becomes especially 
important when one wants to avoid rejection while lowering or discontinuing calcineurin 
inhibitors in order to improve renal function. Prospective validation and assessment of 
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Na orthotope levertransplantatie worden afweeronderdrukkende medicijnen 
(immuunsuppressiva) gegeven om afstoting van de donor-lever tegen te gaan. Deze 
medicamenten hebben hun werking de afgelopen decennia bewezen door een verlaging 
van het aantal (acute) afstotingen (rejecties) na transplantatie. 
Een groep van deze immuunsuppressiva is die van de calcineurine-remmers, waartoe 
cyclosporine en tacrolimus behoren. Een kenmerk van deze medicijnen is hun nauwe 
therapeutische breedte. Onderdosering kan leiden tot rejectie en overdosering kan 
leiden tot het optreden van bijwerkingen, waarvan nierfunctiestoornissen de 
belangrijkste zijn. Adequate dosering van deze medicijnen is daarom uiterst belangrijk. 
De dosering van cyclosporine en tacrolimus gebeurt op basis van het prinicipe van 
“therapeutic drug monitoring” (TDM). Dit houdt in dat op basis van de gemeten 
concentratie van het medicijn in het bloed de dosering zonodig wordt aangepast.  
De monitoring van cyclosporine en tacrolimus gebeurde voornamelijk op basis van de 
dalspiegel van de medicijnen. Dit is de concentratie gemeten net voor inname van de 
medicijnen (C0), welke dus laag is. Voor mycophenolate mofetil is men het er nog niet 
over eens of het principe van TDM een duidelijke meerwaarde op zou leveren of niet. 
 
Cyclosporine 
De afgelopen jaren verschenen artikelen in de literatuur dat het beter zou zijn om 
cyclosporine niet te monitoren op dalspiegel (C0) maar op basis van de concentratie  
2 uur na inname van dit medicijn (C2). Dit tijdspunt zou de totale systemische 
blootstelling van cyclosporine over de periode van 12 uur na inname van dit medicijn 
beter weerspiegelen. Vanwege deze aanbevelingen besloten wij onze 
levertransplantatie patiënten om te zetten van C0 naar C2 monitoring (hoofdstuk 2). 
Na deze omzetting bleek 68% van de patiënten een lagere dosis cyclosporine nodig te 
hebben en bij de overige 32% bleef de dosis gelijk. Er werd een significante verbetering 
van de nierfunctie waargenomen en kleine veranderingen in systolische- en gemiddelde 
ochtend-bloeddrukken bij degenen bij wie de dosis verlaagd was.  
De correlatie van C2 met de oppervlakte onder de concentratie-tijd-grafiek (area under 
the curve, AUC) was beter dan van C0 met de AUC (r² = 0.75 versus r² = 0.64). Wat 
opviel was dat er een duidelijke variabiliteit was binnen patiënten (intra-patiënt 
variabiliteit), terwijl patiënten op dezelfde dosering cyclosporine stonden. Hierdoor 
wordt de C2-monitoring bemoeilijkt en dit kan leiden tot onnodige dosisaanpassingen, 
wat niet goed is voor patiënten, maar ook een onnodige belasting van artsen en 
verpleegkundigen. Het was storend dat 13 van de 21 patiënten van wie de dosering 
verlaagd was, nadat ze 2 keer met een C2 binnen de target range zaten, met dezelfde 
dosis een AUC hadden onder de AUC target range. Hiervan ontwikkelden er 2 zelfs een 
rejectie. Het feit dat 11 van de 13 patiënten geen rejectie ontwikkelden geeft aan dat 
veel patiënten lagere AUCs dan geadviseerd tolereren. Totaal hadden 17 van de 31 
patiënten AUCs buiten de range. De AUC target range die wij hanteren in de kliniek, 
gebaseerd op de algemeen geaccepteerde cyclosporine dalspiegel concentraties van  
90 – 125 µg/L, is 2900 – 3800 h.µg/L.  
Onze gegevens lieten zien dat C0 monitoring vaak leidt tot overdosering, maar dat  
C2 monitoring kan leiden tot perioden van onderdosering en zelfs soms rejectie. Omdat 
de concentratie in het bloed en 12-uurs AUC gerelateerd zijn aan cyclosporine 
blootstelling in de eerste 4 uur na dosering lijkt het logisch om een verkorte curve te 
maken waarin deze concentratiepunten voorkomen teneinde overdosering en 
onderdosering te voorkomen. Een nadeel van deze methode is dat er vaste tijdstippen 
nodig zijn. De ideale situatie zou zijn om een model te hebben dat flexibel is, zonder de 
noodzaak van deze vaste punten en dat dit model gebaseerd is op populatie 
farmacokinetische parameters en op individuele farmacokinetiek.  
Vanwege de noodzaak om de monitoring van cyclosporine te verbeteren hebben wij in 
hoofdstuk 3 verschillende strategieën ontwikkeld. Eén strategie was met behulp van 
formules voor tijdstippen en combinaties van tijdstippen waarop bloed werd 
afgenomen, verkregen met behulp van regressie analyses (limited sampling formulas, 
LSF). De andere strategie was het ontwikkelen van een model, dat gebaseerd is op 
verkorte curves met een beperkt aantal tijdspunten (limited sampling models, LSM). Dit 
model is gebaseerd op geïndividualiseerde populatie farmacokinetiek en op Bayesiaanse 
kansen. De modellen met tijdspunten 0+2h, 0+1+2h, 0+1+3h, 0+2+3h en 0+1+2+3h 
lieten zeer goede correlaties zien met de gouden standaard AUC van 0-12 uur.  Het 
model met alleen tijdspunt C0 was ook nog beter dan de „gewone‟ C0 en C2, zonder 
gebruik te maken van het model. Opvallend was dat het tijdspunt C0 bijna altijd nodig 
was om een goede correlatie te krijgen.   
Het model gebruikt dosering, de tijd van bloedafname, het gewicht van de patiënt en 
de doseringsintervallen. Zowel de kinetiek van de populatie als van het individu zitten 
in het model. De gegevens worden in de computer ingevoerd en een eventuele 
dosiswijziging wordt geadviseerd. Dit model is veel flexibeler dan de limited sampling 
formulas (LSF), waarbij de bloedafname exact op tijd moet gebeuren. 
Het lijkt erop dat dit model met verschillende tijdspunten veel tijd en organisatie kost, 
maar we hebben de ervaring dat dit in de praktijk erg mee valt en dat de voordelen van 
deze methode duidelijk zijn. Het model met de tijdspunten 0+1+2+3h was superieur 
boven de andere modellen (r² = 0.96) en dit model hebben we geïntroduceerd in onze 
kliniek.  
Omdat het wellicht mogelijk zou zijn om bij een toenemend aantal waarnemingen per 
patiënt het aantal bloedafnames per bezoek te verkleinen op de lange termijn, zonder 
daarbij betrouwbaarheid te verliezen, hebben we in hoofdstuk 4 ons model 0+1+2+3h 
geëvalueerd, na dit gedurende 18 maanden te hebben gebruikt. Wat opviel was dat er 
zowel tussen als binnen patiënten een duidelijk verschil was in de tijd tot het bereiken 
van de hoogste cyclosporine concentratie (piek-concentratie). Deze variatie kan 
mogelijk worden veroorzaakt door voedsel of door andere medicatie. Met behulp van 
ons model met meerdere bloedafname momenten is de kans op het missen van deze 
variabiliteit en dus op een verkeerd berekende AUC een stuk kleiner. 
Na de wijziging van C2-montoring naar LSM 0+1+2+3h was er gemiddeld gezien geen 
verschil in cyclosporine dosis, nierfunctie (creatinine klaring) en aantal rejecties. Een 
aantal patiënten eindigde onder de ondergrens van de „target-AUC‟, maar ondanks het 
niet verhogen van de dosis vanwege een slechte nierfunctie volgde er meestal geen 
rejectie. 
De verzamelde data stelden ons in staat om de ware variabiliteit in farmacokinetiek van 
cyclosporine te onderzoeken, welke 15% was. De gemiddelde dosis was 109 mg, wat 
betekent dat een gemiddelde dosisaanpassing van 109 * 15% = 16 mg kan worden 
veroorzaakt door natuurlijke variatie die niet te vermijden is. Als op basis van de 
gemiddelde dosis met een 95% betrouwbaarheidsinterval de AUC target range zou 
worden berekend dan zou deze 2380 – 4390 h.µg/L zijn. Met andere woorden: elke 
AUC waarde binnen deze range zou verklaard kunnen worden door variabiliteit en zou 
daarom niet moeten leiden tot een dosiswijziging. De range die wij aanhouden in de 
kliniek (2900 – 3800 h.µg/L) is veel kleiner en op basis van de huidige gegevens zou 
het in ieder geval theoretisch beter zijn om een andere range aan te nemen, namelijk 
2380 – 3280 h.µg/L. De LSM 0+1+2+3h is dus gezien genoemde variabiliteit mogelijk 
zelfs te nauwkeurig in het schatten van de systemische blootstelling aan cyclosporine. 
Daarom onderzochten we de correlatie tussen modellen met 2 of 3 tijdspunten en 5 
modellen kwamen er goed uit qua correlatie met AUC0-12h en nauwkeurigheid: 0+2h; 
0+3h; 0+1+2h; 0+1+3h and 0+2+3h. De dalspiegel (C0) komt in alle modellen voor, 
wat opnieuw het belang van deze waarde aangeeft, maar alleen in combinatie met de 
andere tijdspunten. Bij het ontwikkelen van de modellen zagen we al eerder een goede 
relatie van deze 2- en 3-puntsmodellen met de gouden standaard 12-uurs AUC. 
Ondanks het feit dat LSM 0+1+2h zowel de piek-concentratiepunten 1 en 2 in zich 
heeft, is de correlatie van dit model niet anders dan LSM 0+2h (r² = 0.84-1.00 vs  
0.81-0.99). Vanwege het feit dat LSM 0+2h gemakkelijker is toe te passen in de 
praktijk en vriendelijker is voor de patiënten, doktoren en verpleegkundigen lijkt dit 




Het monitoren van tacrolimus is in de meeste klinieken, net als aanvankelijk 
cyclosporine, gebaseerd op het meten van de dalspiegel. Wij hebben in hoofdstuk 5 
laten zien dat C0 de systemische blootstelling aan tacrolimus in de eerste 12 uur na 
dosering niet optimaal weergeeft, wat in lijn was met eerdere onderzoeken. Net als 
voor cyclosporine hebben we ook voor tacrolimus een farmacokinetisch model 
ontwikkeld, gebaseerd op populatie gegevens en individuele gegevens van patiënten. 
De modellen C4 en C6 lieten goede correlaties zien met de gouden standaard  
12-uurs AUC in combinatie met uitstekende precisie. 
Het voordeel van onze modellen is dat ze flexibel zijn, in tegenstelling tot andere 
methoden waarbij de bloedafnamen exact op tijd moeten gebeuren, zoals bij de limited 
sampling formulas (LSF). De LSFs lieten in onze studie overigens, net als de modellen 
(LSM), goede resultaten zien, maar de modellen waren net wat beter. Een LSF is wel 
snel met een eenvoudige formule te berekenen. De modellen met meerdere tijdspunten 
waren over het algemeen genomen iets beter dan de modellen met slechts 1 tijdspunt 
van bloedafname, maar omdat LSM 4h en LSM 6h beiden een correlatie van r² = 0.97 
lieten zien was een meerpunts-model niet nodig. Groot voordeel van zo‟n 1-punts 
model is dat het erg praktisch is, patiënten kunnen thuis de medicatie innemen op de 
gebruikelijke tijd en zich 4 tot 6 uur later laten prikken in het ziekenhuis. In theorie 
leidt dit tot minder fouten bij dosering en meting. 
Een beperking van onze studie is dat het model is ontwikkeld op basis van 2 kleine 
groepen patiënten. Vanwege de aanzienlijke schommelingen in de kinetiek van 
tacrolimus net na de transplantatie raden we niet aan om deze modellen te gebruiken 
voor patiënten kort na transplantatie.  
De berekende AUC target range, gebaseerd op C0 (90 – 195 µg/L) is erg breed, wat 
ook aangeeft dat C0-monitoring niet ideaal is. Bij niertransplantatie wordt een nauwere 
range aangehouden (100 – 150 µg/L). Momenteel is er in het veld van de 
levertransplantaties een trend die neigt naar verlaging van de dosis van de (nier 
aantastende) calcineurineremmers, waarvan tacrolimus er een is. Mede op basis van 
onze data hebben we de „AUC targetrange‟ verlaagd naar 90 – 130 h.µg/L (gebaseerd 
op een  
C0 range van 4 – 8 µg/L). De neiging om over te gaan op lagere ranges onderstreept 
nog eens het belang van precieze monitoring van tacrolimus. Momenteel verrichten we 
een studie waarbij de gangbare C0-methode wordt vergeleken met de nieuwe  
4-uurs monitoring, met als uitkomstmaten onder andere de nierfunctie, bloeddruk, 
afstoting en laboratoriumparameters. 
 
Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is een afweer onderdrukkend medicament dat veel wordt 
gebruikt na orgaantransplantatie, waaronder levertransplantatie. In tegenstelling tot 
cyclosporine en tacrolimus heeft MMF geen schadelijke bijwerkingen voor de nieren. 
Het gebruik van MMF kan de dosering van tacrolimus en cyclosporine mogelijk verlagen 
of zelfs geheel overbodig maken. In tegenstelling tot de calcineurineremmers 
cyclosporine en tacrolimus wordt MMF niet gedoseerd op basis van concentraties van 
het medicament in het bloed, maar geldt een vaste dosis, waarbij geen rekening wordt 
gehouden met bijvoorbeeld albumineconcentratie of creatinine klaring. In de literatuur 
kwam naar voren dat het mogelijk toch beter zou zijn in plaats van de vaste doseringen 
over te gaan op TDM. 
In hoofdstuk 6 hebben we het farmacokinetisch gedrag van MMF nader bestudeerd. 
Tijdens deze studie vonden we een lineaire relatie tussen MMF dosis en de trapezoidale 
AUC van MPA, de actieve metaboliet van MMF. Er bleek een grote variatie te zijn in de 
klaring van MPA tussen de patiënten, tot een factor 7 (8.08 – 57.47 L/h).  
Tijdens het onderzoeken van deze variabiliteit bleek er een significante inverse relatie 
te bestaan tussen serum albumine concentratie en klaring van MPA (r² = 0.26, 
p<0.05). Dit betekent dat lage albumine concentraties gerelateerd waren aan een 
toegenomen klaring van MPA. Ook was er een significante relatie tussen creatinine 
klaring en klaring van MPA (r² = 0.36, p<0.05). 
Op basis van klinische selectie hebben we de beschikbare patiëntenpopulatie verdeeld 
in 2 groepen. Groep 1 bestond uit patiënten die MMF gebruikten met een calcineurine 
remmer (CNI) en groep 2 uit patiënten die MMF gebruikten zonder daarnaast een 
calcineurine remmer te gebruiken. Deze twee groepen zijn gebruikt voor verdere 
ontwikkeling van limited sampling modellen. Het model met de combinatie van 
concentratiebepaling van MPA na 0-½-1-2h liet in beide groepen een goede correlatie 
zien met de trapezoidale AUC (met CNI: r²=0.82, MPE/MAPE 14/24;  
zonder CNI: r²=0.85, MPE/MAPE 14/20). 
Verrassend was de goede correlatie van dalspiegels van MPA met de trapezoidale AUC 
voor alle patiënten, zonder het gebruik van een limited sampling model, r²=0.81 
(p<0.05). Met gebruik van de modellen was de correlatie met de trapezoidale AUC 
redelijk in groep 1 (r²=0.89), maar in groep 2 was de correlatie minder sterk 
(r²=0.68).  
Met de ontwikkelde modellen op basis van de momenten van bloedafname 0-½-1-2 uur 
na inname van MMF en het onderscheid in de groepen met/zonder CNI hebben we een 
goede methode om de dosering van MMF nauwkeuriger te sturen. Dit is met name 
belangrijk om afstoting van het transplantaat te voorkomen tijdens het verlagen van de 
dosering van tacrolimus en cyclosporine of zelfs het stoppen van deze CNI‟s.  
Prospectieve validatie van onze modellen en de klinische relevantie van deze modellen 
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behaalde hij het VWO-diploma aan het Paulus Lyceum te Tilburg. In datzelfde jaar 
begon hij met de studie Geneeskunde aan de Universiteit van Antwerpen. In 1996 
stapte hij over naar de Universiteit Leiden, om daar de studie Geneeskunde te 
vervolgen. In 1997 werd de propedeuse behaald. In 2002 werd onder supervisie van  
dr. B. van Hoek een aanvang gemaakt met een onderzoek op de afdeling Maag-, Darm- 
en Leverziekten van het Leids Universitair Medisch Centrum, dat de basis is geweest 
voor dit proefschrift. In 2002 werd het doctoraal examen behaald en na de 
coassistentschappen werd in 2004 het artsexamen behaald te Leiden. Van 2005 tot 
2007 was de auteur huisarts in opleiding aan het Huisartsinstituut Leiden (LUMC), 
waarna hij besloot de richting te kiezen van de beleidsmatige- en organisatorische kant 
van de gezondheidszorg. Na een jaar te hebben doorgebracht aan de faculteit Beleid en 
Management in de Gezondheidszorg (BMG) aan de Erasmus Universiteit te Rotterdam is 
hij sinds 2009 werkzaam als accountmanager bij het bedrijf ZorgDomein Nederland 
B.V., waarbij de visie van verbinden van zorgverleners met als doel de efficiëntie 































































Bij het tot stand komen van dit proefschrift heeft een aantal personen een bijzondere 
bijdrage geleverd, die ik daarvoor graag heel hartelijk wil bedanken. Als eerste mijn 
promotor, professor Bart van Hoek, voor de prettige begeleiding, onvoorwaardelijke 
steun en het vertrouwen dat hij in mij gesteld heeft dit proefschrift te voltooien. Een 
betere promotor had ik mij niet kunnen wensen. Serge Cremers, in de beginperiode van 
het onderzoek live en later via de mail met altijd opbeurende veramerikaniseerde 
opmerkingen en daarnaast deskundig commentaar, mogelijk in omgekeerde volgorde. 
Rogier Press, voornamelijk in de eindperiode van tacrolimus en het „variabele goedje‟ 
MMF. Zelfs toen hij zelf niet meer werkzaam was in het LUMC heeft hij altijd voor mij 
klaar gestaan met goede adviezen, echt fantastisch! Jan den Hartigh voor zijn 
overkoepelende steun vanuit de apotheek en zijn bereidheid om altijd tijd vrij te maken 
voor overleg wanneer dat gewenst was. 
Verder wil ik mijn overige mede-auteurs danken voor hun inspanningen om mijn 
artikelen waar nodig te corrigeren of aan te vullen. 
Ook wil ik graag Eduard van Hoboken en Patrick van der Veek bedanken voor ten 
eerste de gezelligheid op de kamer met muziek waar ik nog te jong voor was (en nog 
steeds ben) en daarnaast ook speciaal voor hun diensten als volleerde infuusprikkers in 
de beginperiode. Mijn zus Alexandra wil ik bedanken omdat ze mij op de juiste 
momenten wist te blijven motiveren. Mijn ouders wil ik hartelijk danken voor de 
interesse, steun en oppasweekenden zodat ik de gelegenheid heb gekregen dit 
proefschrift af te ronden. 
Verder alle stafleden, het secretariaat, de artsen, de verpleegkundigen en overige 
medewerkers van de afdeling Maag-, Darm- en Leverziekten voor hun behulpzaamheid 
door de jaren heen. 
Daarnaast dank ik mijn familie, vrienden en collega‟s voor hun welgemeende interesse 
tijdens het promotietraject. 
En tenslotte wil ik mijn vriendin Tamara heel erg bedanken. Dankzij haar 
onvoorwaardelijke steun de afgelopen jaren is de eindstreep van de promotie behaald. 
Nu weer wat meer tijd voor het gezin! 
 
 
 
 
 
